Proteomic Profiling Identifies Upregulation of Aurora Kinases Causing Resistance to Taxane-type Chemotherapy in Triple Negative Breast Cancer

Proteomic Profiling Identifies Upregulation of Aurora Kinases Causing Resistance to Taxane-type Chemotherapy in Triple Negative Breast Cancer | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Proteomic Profiling Identifies Upregulation of Aurora Kinases Causing Resistance to Taxane-type Chemotherapy in Triple Negative Breast Cancer Bohan Ning, Chang Liu, Ali Cem Kucukdagli, Jiuyi Zhang, Han Jing, and 6 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4889272/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 25 Jan, 2025 Read the published version in Scientific Reports → Version 1 posted 14 You are reading this latest preprint version Abstract Nowadays, chemotherapy and immunotherapy remain the major treatment strategies for Triple-Negative Breast Cancer (TNBC). Identifying biomarkers to pre-select and subclassify TNBC patients with distinct chemotherapy responses is essential. In the current study, we performed an unbiased Reverse Phase Protein Array (RPPA) on TNBC cells treated with chemotherapy compounds and found a leading significant increase of phosphor-AURKA/B/C, AURKA, AURKB, and PLK1, which fall into the mitotic kinase group. The increase of AURKA and AURKB protein was majorly due to a post-transcription level regulation, and Paclitaxel treatment induced Aurora Kinases protein phosphorylation on AURKA(T288)/AURKB(T232) sites and their protein stability. In our UAB TNBC cohort, the expression of AURKA and AURKB was significantly higher in TNBC tumors compared to normal adjacent tissues, and AURKB was found to be highly expressed in African American TNBC patients compared to European Americans. Moreover, Aurora Kinases overexpression in TNBC cells renders resistance to Paclitaxel treatment and attenuates the apoptosis effect triggered by chemotherapy treatment, suggesting Aurora Kinases could mediate the chemo-resistance in TNBC. Hence, a combination of Aurora kinase inhibitors or PROTAC degrader and taxane-type chemotherapy significantly enhanced the chemotherapy effect. In summary, we revealed that Aurora Kinases upregulation after treatment with chemotherapy could confer chemotherapy resistance to TNBC cells, and AURKB could serve as preselection markers for stratifying patients’ response to neoadjuvant chemotherapy. Biological sciences/Cancer Biological sciences/Cancer/Breast cancer Health sciences/Oncology/Cancer Health sciences/Oncology/Cancer/Cancer therapy/Chemotherapy TNBC Cancer Disparity AURKA AURKB Neoadjuvant Chemotherapy Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Introduction Triple-Negative Breast Cancer (TNBC) is one of the subtypes of breast cancer without expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), counting for around 15–20% of all breast cancers 1 , 2 . TNBC is associated with poor long-term outcomes compared to other breast cancer subtypes 3 – 6 . It remains the most challenging subtype to treat because of its aggressive phenotype and limited treatment options. TNBC is insensitive to endocrine and HER2-targeted therapy. It also lacks target therapy strategies probably due to the heterogenous genetic mutation burdens 1 . TNBC has been well studied by multiple omics analysis, and it was suggested to be characterized into four potential subgroups based on their genomic profiling, including two basal-like (BL1, BL2), a mesenchymal (M) and a luminal androgen receptor (LAR) subtype 7 . However, the genomics data fail to identify a useful treatment strategy for all subtypes of TNBC. Therefore, chemotherapy and anti-PD-L1 immunotherapy remain the mainstay of treatment 8 , 9 . It is well known that TNBC is a chemosensitive disease and adjuvant chemotherapy is generally recommended for TNBC patients with stage I (T > 1cm)-III disease 10 . The common chemotherapies for TNBC given to patients include Anthracycline agents such as Adriamycin (Doxorubicin), alkylating agents such as Carboplatin, and Taxane agents such as Paclitaxel 8 . Fluorouracil (5FU) may be given as well. A combination of drugs, or a “chemo cocktail,” is often given to patients and achieves the most favorable tumor inhibition effect. However, not all TNBC patients respond to chemotherapy, suggesting that TNBC is a complicated disease 11 , 12 . Pathologic complete response (pCR) so far remains a validated surrogate biomarker for the prediction of long-term clinical benefit with neoadjuvant chemotherapy because it has been shown to correlate with improved overall survival 13 . Identifying biomarkers to further predict and subdivide TNBC patients with distinct outcomes is of great importance. Three randomized trials evaluated the addition of neoadjuvant carboplatin for the treatment of triple-negative breast cancer: the phase II CALGB 40603; the phase II GeparSixto; and the phase III BrighTNess 14 – 16 . These studies demonstrate that the addition of neoadjuvant carboplatin to anthracycline/taxane chemotherapy improves pCR in unselected TNBC. The overall pCR rate was improved to 55% compared to single-agent chemotherapy 12 . However, higher pathologic complete response rates did not translate to improved event-free survival and this combination strategy also comes with a cost of a significant increase in toxicity. Thus, improved therapeutic approaches with different strategies are desired for TNBC. African-American (AA) women have a high prevalence of TNBC with worse clinical outcomes than European-American (EA) women 17 . Studies found two-fold higher population-based incidence rates of TNBC in AA compared with EA women in all age categories, including the 2015 Annual Report to the Nation on the Status of Cancer 18 , documenting TNBC incidence rates of AA women (27.2 per 100,000) vs. EA women (14.4 per 100,000) respectively. Racial differences in biological factors, such as tumor heterogeneity, population genetics, somatic genomic mutations, and gene expression alterations in AA breast tumors could cause disparities in TNBC 19 . Meanwhile, a large number of non-biologic factors, including socioeconomic deprivation adversities associated with poverty, may adversely contribute to the aggression of TNBC biology in AA women 19 . Moreover, compared to EA women, AA women but not Hispanic or Asian women, have significantly lower rates of pCR for TNBC tumors after receiving neoadjuvant chemotherapy (AA 37% vs. EA 43%, P < 0.001) 20 . The five-year breast cancer-specific survival rates are also significantly lower in AA patients (78.9%) compared with EA patients (88.6%) 21 . However, the cause of the higher mortality rate and lower response rate to neoadjuvant chemotherapy for AA TNBC patients is largely unknown. Aurora kinase A (AURKA) and Aurora kinase B (AURKB) are members of the Aurora kinase subfamily of conserved serine/threonine kinases 22 . AURKA plays a critical role in centrosome duplication and maturation, while AURKB plays a crucial role in cell division as the catalytic protein of the chromosomal passenger complex (CPC) during mitosis by regulating chromosomal alignment, segregation, and cytokinesis 23 . Deregulation of Aurora kinases leads to impairment of mitotic spindle checkpoints causing abnormal spindle assembly and chromosome segregation 24 . Overexpression of AURKA and AURKB has been reported in various types of cancer, including TNBC 25 . Inhibition of Aurora Kinases seems to potentiate the effect of chemotherapy 26 , however, the mechanism of how Aurora kinases contribute to the response of chemotherapy is still elusive and the role of Aurora Kinase in TNBC disparity has not been fully explored. In our study, we tried to explore the expression of Aurora Kinases in patient samples from our UAB TNBC cohort, which included AA and EA patients. The expression of AURKA and AURKB was explored by immunohistochemistry (IHC) to find if these mitosis-related proteins are associated with race, subtypes of TNBC, prognosis and chemotherapy response. Resection and biopsy samples were matched to analyze the level of Aurora Kinases and clinicopathologic features before and after chemotherapy. We also investigated the molecular mechanism underlying how Aurora kinase confers chemotherapy resistance in TNBC cells. Results Clinicopathologic Characteristics of UAB TNBC Cohort To understand whether the biological risk factors driving the disparities result in the aggressive TNBC subtypes, a total of 54 matched TNBC patient samples (Table 1 ) diagnosed at UAB hospital were evaluated, including 28 AA patients (51.9%) and 26 EA patients (48.1%). To investigate the mechanism of racial disparities of genetic contribution to chemotherapy resistance in TNBC, we divided these patients into two groups based on their pathological evaluation: pathological complete response (pCR, n = 28) and residual disease (RD, n = 26) (Table 1 ). After Neoadjuvant chemotherapy treatment, 28 patients (15 AA patients and 13 EA patients) showed a pathologic complete response (pCR), while 26 patients (13 AA patients and 13 EA patients) still had residual disease (RD). The patient’s mean age at diagnosis was 55.5 y for the pCR group and 58.0 y for the RD group. A summary of patients’ clinicopathologic characteristics post neoadjuvant chemotherapy containing pT stage, pN stage, pM stage, histological grade, and lymphovascular invasion (LVI) are depicted in Table 1 . Table 1 Clinicopathological features for TNBC samples of UAB cohort Characteristic Residual disease(n = 26) Pathologic complete response (n = 28) Age (mean, y) 58.0 55.5 Race African America 13/26(50.0%) 15/28(53.6%) European America 13/26(50.0%) 13/28(46.4%) Histological Grade 2 1/26(3.8%) 5/28(17.9%) 3 25/26(96.2%) 23/28(82.1%) T stage T0 0(0%) 26/28(92.9%) Tis 0(0%) 2/28(7.1%) T1 15/26(57.7%) 0(0%) T2 8/26(30.8%) 0(0%) T3 3/26(11.5%) 0(0%) N stage N0 20/26(76.9%) 26/28(92.9%) N1 3/26(11.5%) 2/28(7.1%) N2 1/26(3.9%) 0(0%) N3 2/26(7.7%) 0(0%) M stage M0 23/26(88.5%) 24/28(85.7%) M1 3/26(11.5%) 4/28(14.3%) LVI Present 4/26(15.4%) 0(0%) Absent 22/26(84.6%) 100(100%) LVI = Lymphovascular invasion *Histological grade, TNM stage and LVI was scored in resection samples. The disparity of mitotic count in AA and EA patients Most TNBCs exhibit marked nuclear pleomorphism and increased mitoses 27 . Tumor cell proliferation is a critical component of the Nottingham grading system. It is one of the most powerful prognostic factors 28 , and a well-recognized histo-morphologic predictor of outcome in breast cancer 29 . In this study, we counted the mitotic activity index (MAI) 30 using the Nottingham combined histologic grading system and compared the mitotic score in AAs to that in EAs. In our UAB TNBC cohort, 40 (74.1%) cases identified a mitotic count score of 3. The number of cases in each mitotic count score group (1, 2, and 3) was similar in AA and EA patients, but the mean count of mitosis in AA was slightly higher (p = 0.104) than in EA patients (Fig. 1 A). However, there is no statistically significant difference between EA and AAs in the pCR and RD groups, respectively (Supplementary Fig. 1A). We further subdivided the patients into “mitosis high” (count ≥ 60), and “mitosis low” (count < 60) groups based on the mitosis counts. Chi-square analysis showed that there is a significant association (p = 0.025, \(\:{x}^{2}\) =5.934) between AA patients and “mitosis-high” (Fig. 1 B), suggesting AA TNBC patients have higher number of proliferative cancer cells. Disparity of AURKB expression in AA and EA in biopsy sample As the mitotic score is disproportionally distributed into EA and AA groups, we aim to look at the expression level of those genes regulating the mitosis process and cell division, including Aurora Kinases, and their pattern or distribution in different ethnic groups. We evaluated the expression of AURKA and AURKB using immunohistochemical staining in 54 TNBC cases along with 29 tumor-adjacent normal breast tissue samples (Fig. 1 I). H-Score semi-quantitative analysis of IHC staining showed that AURKA and AURKB were absent or minimally expressed in normal breast tissues adjacent to the tumor (NAT). Statistics analysis showed that AURKA (p < 0.0001) and AURKB (p < 0.0001) expression levels were significantly higher in TNBC tumors compared to NAT, with the average H-score for AURKA and AURKB in TNBC as 37.7 and 86.7, respectively (Fig. 1 C and 1 D). The result is consistent with the report in the TCGA breast cancer dataset (Supplementary Figs. 1B and 1C). Interestingly, the AURKB expression level was much higher in AA patients (Mean H score = 93.59) than in EA patients (Mean H score = 79.06) (Fig. 1 E), and the percentage of AURKB high expression cases (H score ≥ 150) in AA was significantly more than that in EA (Fig. 1 F, P = 0.026, \(\:{x}^{2}\) =4.969). These findings are consistent with the analysis of the publicly available TCGA Breast Cancer dataset and IHC staining pattern of FFPE TNBC tissue samples in the Georgia cohort 25 . On the other hand, although the AURKA expression level was higher in the tumor area than in NAT, no significant difference between EA and AA and no significant difference between pCR and RD groups was identified (Fig. 1 C and Supplementary Fig. 1D-1F). Compared with pCR patients, patients with RD post-neoadjuvant treatment tended to show higher H-scores for AURKB in biopsy (pre-treatment) specimens, although the difference was not statistically significant (p = 0.218, Fig. 1 G). Further analysis revealed that RD EA patients had a significantly higher expression of AURKB in pre-treatment biopsy specimens than pCR EA patients (Fig. 1 H, p = 0.039), suggesting a correlation between the AURKB protein expression levels and chemotherapy resistance in TNBC. Further analysis revealed a linear correlation between the H-scores of AURKA, AURKB, and mitotic count (Fig. 2 A- 2 C). In addition, AURKB-high patients presented higher mitotic count in the pre-treatment biopsy sample than AURKB-low patients (Fig. 2 D, P = 0.003), suggesting AURKB expression is highly correlated with mitosis and tumor cell proliferation in TNBC. AURKA and AURKB Expression in different TNBC subtypes TNBC could be further divided into four molecular subgroups by comprehensive genomics profiling: luminal androgen receptor (LAR), mesenchymal (M), basal-like type 1(BL1), and basal-like type 2(BL2) 7 , 31 . IHC has been used as an alternative way for TNBC subclassification to reduce costs and enhance its compatibility with clinical practice 32 , 33 . Therefore, we used CK5/6 to identify the basal-like group and AR for the LAR group and tried to explore the cancer proliferation index in different TNBC subtypes. In our cohort, 20/54 (37%) cases showed CK5/6 positivity and 18/54 (33.3%) cases showed AR-positivity. Among positive cases, 6 cases expressed both CK5/6 and AR. For the remaining 22 patients, the expression of these two markers was both negative. However, we did not observe any correlation between chemotherapy resistance and any subtypes of TNBC, such as the CK5/6 + basal group or AR + LAR group (Supplementary Fig. 2A). Interestingly, we found that AURKA expression was higher in AR-positive cases than AR-negative cases only in AA patients among the different TNBC subtypes (Supplementary Fig. 2B, P = 0.009). Overall, the mitotic score, AURKA expression, and AURKB expression did not differ among these TNBC subgroups. AURKA and AURKB overexpression confers TNBC cells resistant to Chemotherapy treatment Since we found that AURKB is highly correlated with chemotherapy resistance in TNBC, we intend to examine whether AURKB upregulation causes chemotherapy resistance in TNBC cell lines. We analyzed their expression level in a panel of 13 primary TNBC cell lines (ATCC TNBC panel) based on the RPPA data from Cancer Cell Line Encyclopedia (CCLE) and confirmed by western blot analysis. Based on the race group, we generally divided these TNBC cells into two groups: AA TNBC cells (MDA-MB-468, HCC1806, HCC70, HCC2157, and MDA-MB-157) and EA TNBC cells (MDA-MB-453, BT20, HCC1395, Hs578T, HCC1187, DU4475, and HCC1937) (Fig. 3 A). There was a clear trend that AA TNBC cells had higher levels of AURKB than those in the EA TNBC group, while PLK1 or AURKA expression was not quite different between these two groups. Next, we overexpressed AURKB in BT549 and Hs578T cells or AURKA in HCC1143 and HCC1937 TNBC cells and found that AURKB or AURKA overexpression in TNBC cells renders them more resistant to paclitaxel treatment (Fig. 3 B). In addition, AURKB overexpression in BT549 cells prevented paclitaxel treatment-induced cell death as evidenced by reduced apoptosis marker cleaved-caspase 3 by AURKB overexpression (Fig. 4 A), suggesting upregulation of AURKB expression in TNBC cells could be a strategy for the cancer cells escaping from chemotherapy treatment and mediating the chemo-resistance in TNBC. Taxanes-type chemotherapy treatment upregulates Aurora Kinases expression. Since we found that Aurora Kinases are critical to chemotherapy response, we want to see how these genes change after chemotherapy treatment. It has been reported that EMT could render chemoresistance in TNBC 34 , but we did not observe the EMT markers (E-cadherin and Vimentin) changed in AURKB overexpressing BT549 cells compared to parental BT549 cells (Fig. 4 A). Thus, to probe the molecular basis for differential response to neoadjuvant chemotherapy for TNBC, we performed a comprehensive Reverse Phase Protein Array (RPPA) on MDA-MB-468 cells and MDA-MB-231 cells treated with Docetaxel and Paclitaxel (Fig. 4 B and Supplementary Fig. 1H). Interestingly, we found only a short list of protein changes after chemotherapy. Among them, the most significant changes in protein are phosphor-AURKA/B/C, phosphor-H3(S10), AURKA, AURKB, and PLK1, which fall into the mitotic kinase group (Fig. 4 B and Supplementary Fig. 1H). Phosphorylation of the Serine 10 site on Histone H3 is a hallmark of mitosis, and it is primarily caused by AURKB 35 , 36 and upregulated by Paclitaxel and Docetaxel treatment. By western blot analysis, we have confirmed this finding in multiple TNBC cells, including MDA-MB-468 cells and MDA-MB-231 cells (Fig. 4 C- 4 D). Compounds targeting microtubule depolymerization (Docetaxel and Paclitaxel, Fig. 4 C and 4 D) indeed upregulated AURKB and AURKA expression. However, the platinum compounds (Cisplatin and Carboplatin), antimetabolite compounds (Gemcitabine), and compounds that arrest DNA replication (Epirubicin and Doxorubicin) did not show the same trend (Supplementary Fig. 1G). These data suggest that the upregulation of AURKA and AURKB is unique to the specific type of chemotherapies. In addition, the upregulation of AURKA and AURKB happened in a short time, as soon as 12 hours of paclitaxel treatment (Fig. 5 A). RT-PCR analysis of AURKA and AURKB mRNA levels after Docetaxel and Paclitaxel treatment showed no significant change (< 2 fold) in the mRNA level in the majority of cell lines (Fig. 5 B- 5 C), suggesting a post-transcription level molecular mechanism regulates the upregulation of AURKA and AURKB protein. Chemotherapy treatment upregulated AURKA and AURKB by promoting their protein stability. We next accessed the protein stability of Aurora Kinases in MDA-MB-436 cells treated with 50 µg/mL protein synthesis inhibitor cycloheximide (CHX) with or without Paclitaxel for the indicated time course. As shown in Figs. 6 A and 6 B, compared with the co-treatment of CHX and Paclitaxel, the protein level of AURKB and AURKA decreased more significantly with CHX treatment alone, indicating Paclitaxel extended the lifetime of Aurora Kinases protein and increased the protein stability of AURKB in MDA-MB-436 cells and BT549 cells. In contrast, the protein stability of PLK1 and AURKA increased after paclitaxel treatment in both cell lines but was not as significant as the increase of AURKB. Since we found that Paclitaxel treatment also upregulated Phosphorylation of AURKA (T288) and AURKB (T232) from our RPPA data (Fig. 4 B and Supplementary Fig. 1H) and PhosphoSitePlus® database (Cell Signaling Technology) 37 , 38 , we hypothesis that Paclitaxel treatment promotes AURKB protein stability via upregulating the phosphorylation of AURKB/AURKA at T232/T288 site respectively. To this end, we treated AURKB-T232 phosphorylation inhibitor AZD1152 (Fig. 6 C) or AURKA-T288 kinase inhibitor Alisertib (Fig. 6 D) to inhibit their phosphorylation and activity as shown by the decrease of downstream cascade phosphor-H3-S10, and it also blocked the paclitaxel-induced stability and accumulation of AURKA and AURKB protein in BT549 cells (Fig. 6 C and 6 D), suggesting that phosphorylation of AURKB/AURKA is critical to the protein stability of AURKB/AURKA caused by Paclitaxel treatment. To further test if phosphorylation of the T232 site is the key site for protein stability of AURKB, we have mutated the Threonine 232 site into Alanine (T232A) on HA-tagged AURKB and HA-tagged AURKB-T73A (non-phosphorylatable mutant) vector system. After we stable transfected them into 293T cells and treated with Paclitaxel for 0, 4, 12, 18, and 24 hrs., we found that Paclitaxel treatment increased HA-AURKB expression since 12 hr. time point but not HA-AURKB-T232A expression (Fig. 6 E). In addition, we also performed a dose course of paclitaxel treatment and found Paclitaxel treatment increased HA-AURKB expression at a low concentration of 300nM but not HA-AURKB-T232A expression (Fig. 6 F). Thus, our data suggest that Taxanes-type and Anthracyclines-type chemotherapy treatment could upregulate the phosphorylation of AURKA/B and increase their protein stability. Aurora Kinases inhibition or degradation enhances Paclitaxel treatment in TNBC cells Since we found that Paclitaxel treatment could upregulate the phosphorylation of AURKA/B and increase their protein stability, we hypothesize that Aurora Kinases inhibition or degradation could enhance Paclitaxel treatment in TNBC cells. To this end, we treated HCC1806 TNBC cells with Paclitaxel, Paclitaxel plus AZD1152 (1 µM), Paclitaxel plus Alisertib (1 µM), Paclitaxel plus AURKA PROTAC degrader JB170 (1 µM), or Paclitaxel plus Aurora Kinases pan inhibitor AMG900 (1 µM), and we found that AZD1152, Alisertib and JB170 significantly enhanced the Paclitaxel treatment at very low concentration of 1 nM, which could greatly potentially benefit the patient with minimal side effect or toxicity of chemotherapy (Fig. 7 A). However, the AMG900 effect is not as good as the other three compounds. These data indicated that Aurora Kinases inhibition or degradation indeed enhances Paclitaxel treatment in TNBC cells. Discussion TNBC is the most aggressive breast cancer subtype with poor survival outcomes, and it also lacks reliable predictive biomarkers and therapeutic targets. African American (AA) women with TNBC generally have poorer neoadjuvant chemotherapy response and worse survival rates compared to European American (EA) women 39 . Thus, understanding the molecular mechanism underlying chemotherapy response disparity is crucial. The racial disparities in breast cancer come from both socioeconomic determinants and biological molecular alterations. Previous studies have found that AA patients with TNBC showed higher cell proliferation than their EA counterparts, which is characterized by enriched mitotic count and increased Ki-67 expression 40 , 41 . Tumor cells with a high mitotic index are usually associated with shorter survival and an increased risk of distant recurrence 42 . Our study demonstrates that higher mitotic counts were more frequently observed in AA patients, and AURKB expression in AA patients is higher than in EA patients in TNBC, suggesting the expression of AURKB could contribute to the cancer disparity in TNBC. In addition, the high expression of AURKB is also highly associated with an aggressive feature with a high mitotic rate and high expression of AURKA. This finding is consistent with a previous report in Georgia TNBC cohort 25 and the publicly available TCGA Breast Cancer dataset. Both AURKA and AURKB expression were elevated in the tumor cells compared to NAT. However, our study did not find a significant difference in AURKA expression between AA and EA patients. A possible explanation might be that these two proteins play redundant roles in the same cellular process but have distinct expression patterns and regulations. The expression of AURKB is higher in EA patients who had residual disease after neoadjuvant chemotherapy than those who turned to pathological complete response. The results suggest that the AURKB expression status could serve as a predictor for post-neoadjuvant chemotherapy outcomes for TNBC patients and a valuable biomarker for choosing the right patients who may respond to chemotherapy. However, we did not find a significant correlation between AURKB expression with chemotherapy outcomes in AA TNBC patients. This could be related to the uniformly high expression of AURKB in the pre-treatment biopsy samples of both the residual tumor group and the complete response group in AA patients. The four subtypes of TNBC may respond to different types of therapeutical strategies, and BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines were found to respond to cisplatin preferentially 43 . We have evaluated the correlation of MAI score, Aurora Kinases, and PLK1 expression level within subtypes of TNBC and race/ethnicity status. Interestingly, elevated expression levels of AURKA were observed in AR-positive AA patients compared to the AR-negative group, suggesting AURKA expression is highly correlated with AR expression. Interestingly, previous studies in prostate cancer have also indicated a reciprocal regulation between these two proteins that upregulated the expression of AURKA in prostate cancer cells exhibiting high AR expression levels 44 . Further investigation is warranted to determine whether AURKA could serve as a therapeutic target for AR-positive TNBC. Additionally, it is noteworthy that our results revealed 6 cases exhibiting concurrent positive expression of AR and CK5/6, suggesting IHC methods remain incapable of substituting molecular detection techniques for effective molecular subtyping of TNBC. Thus, it is critical to develop a more effective IHC biomarker for the clinical diagnosis of TNBC subtypes. Previous reports using combined next-generation sequencing and digital RNA expression analysis identified several molecular pathway activations on the residual disease of 74 TNBCs after neoadjuvant chemotherapy 45 . Cell-cycle alterations, including amplification of CDK4/6, AURKA, and loss of CDKN2A, CDKN2B, or RB1, were observed in this study 45 . Our result clearly showed that the mRNA levels of AURKA and AURKB were not significantly changed in TNBC cells treated with chemotherapy, but protein and phosphorylation levels were dramatically altered, as shown by RPPA array and western blot, suggesting RPPA array, proteomics, and IHC analysis could be more accurate than next generation sequencing genomics profiling to dissect the molecular mechanism of chemotherapy resistance in TNBC. Previous Quantitative phosphoproteomics have identified four potential phosphorylation sites on AURKB- p-T232, p-T236, p-S313, and p-S331 after Taxol treatment which is similar to paclitaxel treatment in PhosphoSitePlus® database powered by Cell Signaling Technology 37 . We identified phosphorylation on T232 site was critical for Paclitaxel induced phosphorylation and protein stability of AURKB, leading to a combinatory therapy strategy with Aurora Kinases inhibition and chemotherapy. Chemotherapy like paclitaxel or Doxorubicin usually leads to cell cycle arrest or apoptosis 46 . Paclitaxel is an anti-mitotic agent that binds to microtubules and stabilizes them against depolymerization, and deacetylation of a-tubulin induces microtubule depolymerization and results in microtubule instability 47 and diminishes the effect of chemotherapy treatment-induced microtubule stability. Our study has showed that AURKB overexpression attenuates the apoptosis effect caused by Paclitaxel treatment, and inhibition of both Aurora A and B kinases have been shown to significantly increase apoptosis and reduce proliferation in TNBC cells 48 , 49 . Thus, Aurora Kinases could regulate chemotherapy resistance through destabilizing microtubules, and it may shed light on the mechanism underlying the chemotherapy resistance and worth further investigation. Materials and Methods Patient Cohort We retrospectively identified 54 TNBC patients who underwent neoadjuvant chemotherapy at the University of Alabama at Birmingham (UAB) Hospital between 2011 and 2023, with available matched formalin-fixed paraffin-embedded core needle biopsy samples and surgical resection samples. TNBC was defined as breast cancer that was negative for ER (< 1%), PR (< 1%), and negative for HER2 overexpression (score 0, 1 and 2) by IHC and HER2 amplification by silver-enhanced in situ hybridization. Clinicopathological characteristics, including treatment and prognosis information, were collected from the electronic medical records. This study was approved by the Institutional Review Board of UAB (IRB-300011620). Due to the retrospective nature of the study, Institutional Review Board waived the need of obtaining informed consent. All experiments were performed in accordance with relevant guidelines and regulations. Histologic Evaluation Hematoxylin and eosin (H&E)-stained slides from all the cases were reviewed by two experienced pathologists. World Health Organization classification and Nottingham combined histologic grading system were used to identify tumor histologic subtypes and grades. In all biopsy slides, mitoses were counted in 10 consecutive high-power fields (HPFs). Based on a microscope field diameter of 0.50 mm, counts of 0 to ≤ 7, 8–14 and ≥ 15 mitoses per 10 HPFs corresponded to mitotic scores of 1, 2, and 3, respectively as previously described 30 . The case was considered “high-mitosis” when the mitotic count was equal to or greater than 60. Immunohistochemical Staining and Evaluation IHC staining was performed on formalin-fixed, paraffin-embedded tumor tissue samples retrieved from the Department of Pathology at UAB Hospital. The slides were baked on a slide warmer for 1.5h at 70℃. After deparaffinization and rehydrated, the heat-induced antigen retrieval method was performed with citrate buffer (pH 6.0, Abcam, ab93678) for 30min. The slides were then incubated with primary antibody at 4°C overnight. The following antibodies and dilutions were used: AURKA (#91590 from Cell Signaling Technology, Inc., USA, 1:100), AURKB (NBP2-61493, Novus Biologicals, LLC, 1:100), cytokeratin 5/6 (M7237, Agilent Technologies, USA,1:50), androgen receptor (200R-17, Sigma-Aldrich, USA, 1:100). Goat anti-Rabbit horseradish peroxidase-conjugated antibody (31460, Thermo Scientific, USA, 1:100) and goat anti-mouse horseradish peroxidase-conjugated antibody (31430, Thermo Scientific, USA, 1:100) was used as the secondary antibody. After incubated in DAB (34000, Thermo scientific, USA), all slides were counterstained with Mayer’s Haematoxylin applied for 2 min. AURKA and AURKB expression was evaluated by the H-score system. Any level of cytoplasmic or nuclear staining of AURKA and nuclear staining of AURKB was considered positive. Lymph node tissue was used as positive control. The intensity was classified into four categories (none, 0; weak, 1+; moderate, 2+; and strong, 3+). The percentage of positive tumor cells was estimated. H-scores were calculated by multiplying the percentage of positive tumor cells by the corresponding intensity of AURKA/AURKB expression, with total scores ranging from 0 to 300. The case was considered “AURKA-high” when the H-score of AURKA was higher than 100. “AURKB-high” was considered when the H-score of AURKB was equal or greater than 150. The percentage of positive tumor cells of androgen receptor (AR) and cytokeratin 5/6 (CK5/6) was evaluated in nuclear and membrane, respectively. When positive staining show in > 1% of tumor cells, the case was considered positive. Statistical Analysis All data were analyzed using SPSS version 25.0 software for Windows (SPSS, Chicago, IL, USA) as previously described 50 . T-test and Wilcoxon signed-rank test were used to show the difference in mitotic count H-score between different groups. The chi-square test or Fisher exact test was used as appropriate to analyze the relationship between mitotic count, AURKA-high, AURKB-high, and clinical characteristics. A P value of ≤ 0.05 was considered statistically significant. Cell Culture: TNBC panel cell lines (ATCC-TCP-1001, TCP-1002, TCP-1003) including BT549, MDA-MB-468, MDA-MB-231, MDA-MB-453, MDA-MB-436, HCC1395, and HCC1806 cell lines were purchased from ATCC. Cell lines were regularly tested in the lab for mycoplasma. All cells were cultured at 37°C and 5% CO2. MDA-MB-468, MDA-MB-453 and MDA-MB-436 cells were cultured in 1X DMEM with 10% fetal bovine serum (Corning 35-011-CV) and 1X Penicillin/Streptomycin. Cells culture media was changed every 3–4 days and cells were passaged using 0.05% or 0.25% trypsin. Corning Media includes DMEM: 10-013-CV, RPMI: 10-040-CV, 50/50 DMEM/ Ham’s F-12: 10-090-CV. Drug Treatments: Paclitaxel (Med Chem Express, HY-B0015), Docetaxel (Selleckchem, S1148), Doxorubicin (Selleckchem, S1208), Epirubicin (Selleckchem, S1223), Cycloheximide (CHX, Selleckchem, S7418), Alisertib (Med Chem Express, HY-10971), Barasertib (AZD1152-HQPA) (Selleckchem, S1147), JB170 (Med Chem Express, HY-141512), AMG-900 (Selleckchem, S2719), Cisplatin (Selleckchem, S1166), Gemcitabine (Selleckchem, S1714 ), Irinotecan (Selleckchem, S1198), were dissolved in DMSO at a concentration of 10 mM. Control is treatment with equal volume of DMSO. Doxorubicin: Doxorubicin hydrochloride (Sigma 44583-1MG) was dissolved in DMSO. Generation of overexpression cells: For stable overexpression of AURKA, AURKB, AURKB(T232A) in BT549, HCC1143, HCC1937, and 293T cells, Lentiviral plasmid p7052 pHAGE-P-CMVt-N-HA-GAW-AURKB (Cat# 100142), and pHR_dSV40-Aurora A-GFP(Cat#67924) were purchased from Addgene. AURKB (T232A) mutations were made using QuickchangeII XL site directed mutagenesis kit (Agilent, Cat# 200522) as previously described 51 . Lentiviral plasmids were transfected as previously described 51 into the packaging cells 293T cells together with two other plasmids: packaging DNA (psPAX2) and envelope DNA (pMD2G) through Lipofectamine transfection. After 48 hrs transfection, viruses were collected, filtered, and used to infect TNBC cells in the presence of 8–10 µg/mL polybrene for 24 hrs. The infected cells were selected with 4–8 µg/mL puromycin 51 . BRNA extraction, RT-PCR (reverse-transcription–polymerase chain reaction) and quantitative real-time RT-PCR As previously described RT-PCR method 52 , total RNA from cells was isolated using Trizol reagent (Invitrogen) and protocol was followed as per the manufacturer’s instructions. 1 µg of total RNA was reverse transcribed into cDNA using iScript™ cDNA synthesis kit (Biorad) following the manufacturer’s instructions. Then, an equivalent volume (1 µl) of cDNA was used as a template for quantitative real-time PCR with iQ™ SYBR Green Supermix (Biorad) and the StepOnePlus™ (Applied Biosystems) instrument according to the manufacturer’s instructions. The names of the genes quantified and the sequences of the primers are given in the following table. The threshold cycles for specific targets were then normalized to the threshold cycles of GAPDH to calculate the relative fold-change difference 52 . qRT-PCR primers: primers sequence AURKB-Forward 5’-CAGTGGGACACCCGACATC-3’ AURKB-Reverse 5’-GTACACGTTTCCAAACTTGCC-3’ AURKA-Forward 5’-GAGGTCCAAAACGTGTTCTCG-3’ AURKA-Reverse 5’-ACAGGATGAGGTACACTGGTTG-3’ GAPDH-Forward 5’-GGAGCGAGATCCCTCCAAAAT-3’ GAPDH-Reverse 5’-GGCTGTTGTCATACTTCTCATGG-3’ Immunoblotting: Immunoblotting was performed as previously described 51 . Protein lysates were loaded into 4–12% Bis-Tris gels and resolved by electrophoresis. Samples were then blotted on PVDF membrane (Millipore IPVH00010) using the semi-dry transfer technique (Bio-Rad). Membranes were visualized using autoradiography film (Denville E3018) 51 . Primary Antibodies: β-actin (Sigma #A5316), Aurora B/AIM1 (E3R8N) (CST#28711), Aurora A (D3V7T) (CST#91590), Phospho-Aurora A (Thr288)/Aurora B (Thr232)/Aurora C (Thr198) (D13A11)(CST#2914), PLK1 (208G4)(CST#2914), HA-Tag (C29F4) (CST#3724), Cleaved-Caspase 3 (CST#9664) were from Cell Signaling Technology. Secondary Antibodies: Mouse (Thermo 31430), Rabbit (Thermo 31460). Colony formation assay Colony formation assay was performed as previously described 51 . Cells were cultured for 12–17 days in the presence of different compounds. Media with compound was replenished every two days. At the end of the experiment, media was aspirated, and viable cells were stained with 0.5% crystal violet dye 51 . Reverse phase protein array (RPPA): RPPA was performed in MDACC Functional Proteomics core facility as previously described 51 , 52 . Briefly, cellular proteins were denatured by 1% SDS, serially diluted, and spotted on nitrocellulose-coated slides. Each slide was probed with a validated primary antibody plus a biotin-conjugated secondary antibody. The signal obtained was amplified using a Dako Cytomation–catalyzed system and visualized by DAB colorimetric reaction. The slides were analyzed using customized Microvigene software (VigeneTech Inc., Carlisle, MA). Each dilution curve was fitted with a logistic model (“SuperCurve Fitting” developed at MDACC) and normalized by median polish. The data were further adjusted for batch effects by normalizing identical control samples in this set with an invariant control sample set and applying the adjustment to each corresponding data point. The heatmap was then generated using R version 4.1.0 with the normalized data that have also been median centered by antibodies. The data clustering was performed using Cluster 3.0 (centered by gene, followed by hierarchical clustering by gene and array using complete linkage) and TreeView 51 , 52 . TCGA data analysis in the Tumor Immune Estimation Resource (TIMER) database : TCGA gene expression data analysis was performed in the Tumor Immune Estimation Resource (TIMER) ( https://cistrome.shinyapps.io/timer/ ) database as previously described 53 . Gene_DE module allows users to study the differential expression between tumor and adjacent normal tissues for any gene of interest across all TCGA tumors. Distributions of gene expression levels are displayed using box plots. The statistical significance computed by the Wilcoxon test is annotated by the number of stars (*: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001). Users can identify genes that are up-regulated or down-regulated in the tumors compared to normal tissues for each cancer type, as displayed in gray columns when normal data are available 53 . Declarations Competing interests The authors declare no competing interests. Ethics declarations Ethics approval and consent to participate This project was approved by the Institutional Review Boards of the University of Alabama at Birmingham(IRB-300011620). Due to the retrospective nature of the study, Institutional Review Board waived the need of obtaining informed consent. Author Contribution Conception and design: BN, CL, HG, JX; providing access to clinical samples: BN, HG; Performing experiments, ethics approval, pathological reviews, acquisition of data, analysis and interpretation of data: BN, CL, ACK, JZ, HJ, ZZ, YZ, YD, YC, HG, JX; Statistical support: BN, YC; Drafted the manuscript: BN, CL, JX. All authors read and approved the final manuscript; overall study supervision: GH, JX. Acknowledgments: This research was supported in part by the Startup Fund and Impact Award from the Heersink School of Medicine at the University of Alabama at Birmingham (to J. Xu) and the Breast Cancer Research Foundation of Alabama (to J. Xu). RPPA dataset has been performed by a core facility at the University of Texas-M.D. Anderson Cancer Center at Houston. Data Availability Data is provided within the manuscript or supplementary information files. References Ciriello, G. et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell . 163 , 506–519. https://doi.org/10.1016/j.cell.2015.09.033 (2015). Parker, J. S. et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. J. Clin. Oncol. 41 , 4192–4199. https://doi.org/10.1200/JCO.22.02511 (2023). Liedtke, C. et al. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. J. Clin. Oncol. 41 , 1809–1815. https://doi.org/10.1200/JCO.22.02572 (2023). Kohler, B. A. et al. Annual Report to the Nation on the Status of Cancer, 1975–2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J Natl Cancer Inst 107, djv048 (2015). https://doi.org/10.1093/jnci/djv048 Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13 , 4429–4434 (2007). Carey, L. A. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13 , 2329–2334 (2007). Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121 , 2750–2767. https://doi.org/10.1172/JCI45014 (2011). Ferreira, A. R., Metzger-Filho, O., Sarmento, R. M. B. & Bines, J. Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02). Front. Oncol. 7 , 329. https://doi.org/10.3389/fonc.2017.00329 (2017). Emens, L. A. et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann. Oncol. 32 , 983–993. https://doi.org/10.1016/j.annonc.2021.05.355 (2021). Coates, A. S. et al. Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann. Oncol. 26 , 1533–1546. https://doi.org/10.1093/annonc/mdv221 (2015). Carey, L. A. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13 , 2329–2334. https://doi.org/10.1158/1078-0432.CCR-06-1109 (2007). Sharma, P. et al. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clin. Cancer Res. 23 , 649–657. https://doi.org/10.1158/1078-0432.CCR-16-0162 (2017). Yau, C. et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 23 , 149–160. https://doi.org/10.1016/S1470-2045(21)00589-1 (2022). Shepherd, J. H. et al. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J. Clin. Oncol. 40 , 1323–1334. https://doi.org/10.1200/JCO.21.01506 (2022). von Minckwitz, G. et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 15 , 747–756. https://doi.org/10.1016/S1470-2045(14)70160-3 (2014). Geyer, C. E. et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann. Oncol. 33 , 384–394. https://doi.org/10.1016/j.annonc.2022.01.009 (2022). Newman, L. A. & Kaljee, L. M. Health Disparities and Triple-Negative Breast Cancer in African American Women: A Review. JAMA Surg. 152 , 485–493. https://doi.org/10.1001/jamasurg.2017.0005 (2017). Kohler, B. A. et al. Annual Report to the Nation on the Status of Cancer, 1975–2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J Natl Cancer Inst 107, djv048 (2015). https://doi.org/10.1093/jnci/djv048 Prakash, O. et al. Racial Disparities in Triple Negative Breast Cancer: A Review of the Role of Biologic and Non-biologic Factors. Front. Public. Health . 8 , 576964. https://doi.org/10.3389/fpubh.2020.576964 (2020). Killelea, B. K. et al. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. J. Clin. Oncol. 33 , 4267–4276. https://doi.org/10.1200/JCO.2015.63.7801 (2015). Bandera, E. V., Maskarinec, G., Romieu, I. & John, E. M. Racial and ethnic disparities in the impact of obesity on breast cancer risk and survival: a global perspective. Adv. Nutr. 6 , 803–819. https://doi.org/10.3945/an.115.009647 (2015). Carmena, M. & Earnshaw, W. C. The cellular geography of aurora kinases. Nat. Rev. Mol. Cell. Biol. 4 , 842–854. https://doi.org/10.1038/nrm1245 (2003). Lens, S. M., Voest, E. E. & Medema, R. H. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat. Rev. Cancer . 10 , 825–841. https://doi.org/10.1038/nrc2964 (2010). Keen, N. & Taylor, S. Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer . 4 , 927–936. https://doi.org/10.1038/nrc1502 (2004). Garlapati, C. et al. PLK1 and AURKB phosphorylate survivin differentially to affect proliferation in racially distinct triple-negative breast cancer. Cell. Death Dis. 14 , 12. https://doi.org/10.1038/s41419-022-05539-5 (2023). Bush, T. L. et al. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models. Mol. Cancer Ther. 12 , 2356–2366. https://doi.org/10.1158/1535-7163.MCT-12-1178 (2013). Palma, G. et al. Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget . 6 , 26560–26574. https://doi.org/10.18632/oncotarget.5306 (2015). van Diest, P. J., Brugal, G. & Baak, J. P. Proliferation markers in tumours: interpretation and clinical value. J. Clin. Pathol. 51 , 716–724. https://doi.org/10.1136/jcp.51.10.716 (1998). Rakha, E. A. et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J. Clin. Oncol. 26 , 3153–3158. https://doi.org/10.1200/JCO.2007.15.5986 (2008). Arispe Angulo, K. R. et al. A high mitotic score in breast cancer after neoadjuvant chemotherapy is predictive of outcome and associated with a distinct morphology. Histopathology . 76 , 661–670. https://doi.org/10.1111/his.14049 (2020). Burstein, M. D. et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin. Cancer Res. 21 , 1688–1698. https://doi.org/10.1158/1078-0432.CCR-14-0432 (2015). Kim, S. et al. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers. Clin. Breast Cancer . 18 , e1123–e1132. https://doi.org/10.1016/j.clbc.2018.03.012 (2018). Zhao, S. et al. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. Oncologist . 25 , e1481–e1491. https://doi.org/10.1634/theoncologist.2019-0982 (2020). Fischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature . 527 , 472–476. https://doi.org/10.1038/nature15748 (2015). Hirota, T., Lipp, J. J., Toh, B. H. & Peters, J. M. Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature . 438 , 1176–1180 (2005). Hsu, J. Y. et al. Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell . 102 , 279–291 (2000). Kettenbach, A. N. et al. Quantitative phosphoproteomics identifies substrates and functional modules of Aurora and Polo-like kinase activities in mitotic cells. Sci. Signal. 4 , rs5. https://doi.org/10.1126/scisignal.2001497 (2011). Tyler, R. K., Shpiro, N., Marquez, R. & Eyers, P. A. VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Cell. Cycle . 6 , 2846–2854 (2007). Woriax, H. E. et al. Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy. J. Clin. Oncol. JCO2301199 https://doi.org/10.1200/JCO.23.01199 (2024). Sullivan, H. C. et al. Triple-negative breast carcinoma in African American and Caucasian women: clinicopathology, immunomarkers, and outcome. Appl. Immunohistochem. Mol. Morphol. 22 , 17–23. https://doi.org/10.1097/PAI.0b013e318281148e (2014). Mremi, A. et al. Breast cancer in Tanzanian, black American, and white American women: An assessment of prognostic and predictive features, including tumor infiltrating lymphocytes. PLoS One . 14 , e0224760. https://doi.org/10.1371/journal.pone.0224760 (2019). Stuart-Harris, R., Caldas, C., Pinder, S. E. & Pharoah, P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast . 17 , 323–334. https://doi.org/10.1016/j.breast.2008.02.002 (2008). Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121 , 2750–2767. https://doi.org/10.1172/JCI45014 (2011). Kivinummi, K. et al. The expression of AURKA is androgen regulated in castration-resistant prostate cancer. Sci. Rep. 7 , 17978. https://doi.org/10.1038/s41598-017-18210-3 (2017). Balko, J. M. et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov . 4 , 232–245. https://doi.org/10.1158/2159-8290.CD-13-0286 (2014). Anand, U. et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 10 , 1367–1401. https://doi.org/10.1016/j.gendis.2022.02.007 (2023). Matsuyama, A. et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 21 , 6820–6831. https://doi.org/10.1093/emboj/cdf682 (2002). Kai, K. et al. Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Mol. Cancer Ther. 14 , 2687–2699. https://doi.org/10.1158/1535-7163.MCT-15-0096 (2015). Kawai, M., Nakashima, A., Kamada, S. & Kikkawa, U. Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family. J. Biomed. Sci. 22 , 48. https://doi.org/10.1186/s12929-015-0150-2 (2015). Yang, G. et al. Career choice regret during COVID-19 among healthcare students and professionals in mainland China: a cross-sectional study. BMC Med. Educ. 21 , 534. https://doi.org/10.1186/s12909-021-02972-6 (2021). Xu, J. et al. AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway-Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B. Cancer Discov . 11 , 3064–3089. https://doi.org/10.1158/2159-8290.CD-20-0815 (2021). Xu, J. et al. 14-3-3zeta turns TGF-beta's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. Cancer Cell. 27 , 177–192. https://doi.org/10.1016/j.ccell.2014.11.025 (2015). Li, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48 , W509–W514. https://doi.org/10.1093/nar/gkaa407 (2020). Additional Declarations No competing interests reported. Supplementary Files 29JiaXuAliCemKucukdagliA.xlsx 29JiaXuAliCemKucukdagliB.xlsx SupplementaryFigure1.jpg Supplement Figure 1. Expression of AURKA and AURKB in AA and EA TNBC patients. A:Mitotic count in AA and EA TNBC patient with different chemotherapy outcomes. B-C: The expression of AURKA(B) and AURKB(C) in normal breast tissue and breast tumor from TCGA dataset. D: The expression of AURKA in normal breast tissue and TNBC tumors between AA and EA TNBC patients. E: The H-score of AURKA IHC staining in patients with different chemotherapy outcomes including pathological complete response(pCR) and resident disease (RD). F: H-score of AURKA IHC staining in AA and EA TNBC patients with different chemotherapy outcomes. Data are presented as the medians and SD as determined with an independent samples t-test or a Mann–Whitney U test. G: IB analysis of Aurora Kinases expression in TNBC cells treated with Cisplatin, Gemcitabine, or Irinotecan chemotherapy. H:RPPA analysis of TNBC cells treated with Paclitaxel chemotherapy (Full Heatmap). SupplementaryFigure2.jpg Supplement Figure 2. Aurora Kinases expression in different subtypes of TNBC. A. Percentage of CK5/6 positive case (Left) and AR positive case (Right) in TNBC chemotherapy pCR and RD group. Data are presented as the percentage of cases as determined with a Chi-square test. B.AURKA expression in African America TNBC patients with positive AR expression or negative AR expression. Data is presented as the medians and standard deviation (SD) as determined with a Mann–Whitney U test. Supplementaryfileoriginalfilm.pdf Cite Share Download PDF Status: Published Journal Publication published 25 Jan, 2025 Read the published version in Scientific Reports → Version 1 posted Editorial decision: Revision requested 01 Dec, 2024 Reviews received at journal 01 Dec, 2024 Reviews received at journal 30 Nov, 2024 Reviews received at journal 28 Nov, 2024 Reviewers agreed at journal 18 Nov, 2024 Reviewers agreed at journal 18 Nov, 2024 Reviewers agreed at journal 18 Nov, 2024 Reviewers agreed at journal 18 Nov, 2024 Reviewers agreed at journal 18 Nov, 2024 Reviewers invited by journal 18 Nov, 2024 Editor assigned by journal 22 Aug, 2024 Editor invited by journal 22 Aug, 2024 Submission checks completed at journal 21 Aug, 2024 First submitted to journal 09 Aug, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4889272","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":355044297,"identity":"e48ac0cf-0c68-4e90-a481-b95cd7740a4e","order_by":0,"name":"Bohan Ning","email":"","orcid":"","institution":"University of Alabama at Birmingham","correspondingAuthor":false,"prefix":"","firstName":"Bohan","middleName":"","lastName":"Ning","suffix":""},{"id":355044298,"identity":"2b237209-41e8-46df-9bab-7318b29f938e","order_by":1,"name":"Chang Liu","email":"","orcid":"","institution":"University of Alabama at Birmingham","correspondingAuthor":false,"prefix":"","firstName":"Chang","middleName":"","lastName":"Liu","suffix":""},{"id":355044299,"identity":"2046088f-906a-49e7-b36e-2097cc84a592","order_by":2,"name":"Ali Cem Kucukdagli","email":"","orcid":"","institution":"University of Alabama at Birmingham","correspondingAuthor":false,"prefix":"","firstName":"Ali","middleName":"Cem","lastName":"Kucukdagli","suffix":""},{"id":355044300,"identity":"41047c48-f621-4ccb-b63a-f3d9a8278051","order_by":3,"name":"Jiuyi Zhang","email":"","orcid":"","institution":"University of Alabama at Birmingham","correspondingAuthor":false,"prefix":"","firstName":"Jiuyi","middleName":"","lastName":"Zhang","suffix":""},{"id":355044303,"identity":"95fb851b-c7bd-42cc-b038-0a232ad97ad2","order_by":4,"name":"Han Jing","email":"","orcid":"","institution":"University of Alabama at Birmingham","correspondingAuthor":false,"prefix":"","firstName":"Han","middleName":"","lastName":"Jing","suffix":""},{"id":355044304,"identity":"a610451a-5739-4fa7-ae81-7fda04395371","order_by":5,"name":"Zhiqian Zhou","email":"","orcid":"","institution":"University of Alabama at Birmingham","correspondingAuthor":false,"prefix":"","firstName":"Zhiqian","middleName":"","lastName":"Zhou","suffix":""},{"id":355044306,"identity":"ef3891da-9762-4557-8b2d-4bebc4db6953","order_by":6,"name":"Yuwei Zhang","email":"","orcid":"","institution":"University of Alabama at Birmingham","correspondingAuthor":false,"prefix":"","firstName":"Yuwei","middleName":"","lastName":"Zhang","suffix":""},{"id":355044307,"identity":"9e0418a3-0288-46e3-84c6-9ef3b6141eae","order_by":7,"name":"Ying Dong","email":"","orcid":"","institution":"Peking University First Hospital","correspondingAuthor":false,"prefix":"","firstName":"Ying","middleName":"","lastName":"Dong","suffix":""},{"id":355044313,"identity":"21798402-4cc6-4083-bede-3e9560cf5dbc","order_by":8,"name":"Yunjia Chen","email":"","orcid":"","institution":"University of Alabama at Birmingham","correspondingAuthor":false,"prefix":"","firstName":"Yunjia","middleName":"","lastName":"Chen","suffix":""},{"id":355044317,"identity":"6fc410a9-bc40-435e-b3fd-a13652dc5820","order_by":9,"name":"Hua Guo","email":"","orcid":"","institution":"University of Alabama at Birmingham","correspondingAuthor":false,"prefix":"","firstName":"Hua","middleName":"","lastName":"Guo","suffix":""},{"id":355044318,"identity":"1b956fc4-b4b5-4af7-92b2-7c4dc9949999","order_by":10,"name":"Jia Xu","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAmElEQVRIiWNgGAWjYHCCxAcMDAeAdALxWpINSNbCJkGaFoMbCc+qeWruMPCz5xgQp0VyRkLabZ5jzxgke94QqYVfAqSF7TDQOmJtYQNqKeb5d5jBnmgtIFuYeduAtkgQ7ZeeB8mSc/ue8UiceVZAnBaD4zmJH958uyPH3568gTgtDAw8CWCSWOUgwH6AFNWjYBSMglEwEgEAmwkrD7lm/dsAAAAASUVORK5CYII=","orcid":"","institution":"University of Alabama at Birmingham","correspondingAuthor":true,"prefix":"","firstName":"Jia","middleName":"","lastName":"Xu","suffix":""}],"badges":[],"createdAt":"2024-08-09 22:38:17","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4889272/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4889272/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41598-025-87315-x","type":"published","date":"2025-01-25T15:57:07+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":66660591,"identity":"36afee61-8501-419b-a051-ac3059cd603c","added_by":"auto","created_at":"2024-10-15 08:48:50","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":21956381,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMitotic count and expression of AURKA and AURKB in AA and EA patients.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eA:\u003c/strong\u003eMitotic count in AA and EA TNBC patients.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eB:\u003c/strong\u003eDistribution of ‘mitosis-high’ cases between EA and AA TNBC patients.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eC-D:\u003c/strong\u003eDifferential expression of AURAKA (\u003cstrong\u003eC\u003c/strong\u003e) and AURKB (\u003cstrong\u003eD\u003c/strong\u003e) between normal breast tissue and TNBC tumors.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eE:\u003c/strong\u003e The expression of AURKB in normal breast tissue and TNBC between AA and EA patients.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eF:\u003c/strong\u003eDistribution of ‘AURKB-high’ cases between EA and AA TNBC patients.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eG:\u003c/strong\u003e The H-score of AURKB IHC staining in patients with different chemotherapy outcomes including pathological complete response(pCR) and resident disease (RD).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eH:\u003c/strong\u003e H-score of AURKB IHC staining in AA and EA TNBC patients with different chemotherapy outcomes.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eI:\u003c/strong\u003e Representative images of HE and IHC staining of AURKA and AURKB in Normal Adjacent Tissue (NAT) and TNBC tumors from AA and EA patients. Scale bars: 20 μm.\u003c/p\u003e\n\u003cp\u003eData are presented as the medians and standard deviation (SD) as determined with an independent samples t-test (\u003cstrong\u003eA, G\u003c/strong\u003e and \u003cstrong\u003eH †\u003c/strong\u003e) or a Mann–Whitney U (\u003cstrong\u003eC-E, H*\u003c/strong\u003e) test. Data are presented as the percentage of cases as determined with a Chi-square test (\u003cstrong\u003eB \u003c/strong\u003eand \u003cstrong\u003eF\u003c/strong\u003e).\u003c/p\u003e","description":"","filename":"Figure1.png","url":"https://assets-eu.researchsquare.com/files/rs-4889272/v1/81ba8d0f092b059d89108cd0.png"},{"id":66658631,"identity":"ae984b57-c41e-42cf-b7af-2ddbb6f494da","added_by":"auto","created_at":"2024-10-15 08:32:50","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":2614982,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eThe correlation between AURKA, AURKB and mitotic count.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eA-C:\u003c/strong\u003e Moderate correlation between AURKA and AURKB (\u003cstrong\u003eA\u003c/strong\u003e), AURKA and mitotic count (\u003cstrong\u003eB\u003c/strong\u003e), AURKB and mitotic count (\u003cstrong\u003eC\u003c/strong\u003e).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eD:\u003c/strong\u003eDifferent distribution of mitotic count in AURKB-high and AURKB-low cases.\u003c/p\u003e\n\u003cp\u003eData are presented as the medians and SD as determined with an independent samples t-test (\u003cstrong\u003eD\u003c/strong\u003e).\u003c/p\u003e","description":"","filename":"Figure2.png","url":"https://assets-eu.researchsquare.com/files/rs-4889272/v1/35898624be82eae0abc566d8.png"},{"id":66657965,"identity":"1a9e54d7-d857-4e5b-81e1-69e7a3770d0c","added_by":"auto","created_at":"2024-10-15 08:24:50","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":16903417,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eAurora Kinases overexpression render TNBC cells resistance to Paclitaxel treatment\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eA:\u003c/strong\u003e Immunoblotting (IB) analysis of AURKA, AURKB, and PLK1 in AA and EA TNBC cell lines.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eB:\u003c/strong\u003eColony Formation assay analysis of indicated TNBC cells treated with chemotherapy drug Paclitaxel in indicated concentration.\u003c/p\u003e","description":"","filename":"Figure3.png","url":"https://assets-eu.researchsquare.com/files/rs-4889272/v1/b56dfba6aa983775ce78547d.png"},{"id":66660045,"identity":"105149f0-0974-416b-883b-713f4ace3847","added_by":"auto","created_at":"2024-10-15 08:40:50","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":4210307,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ePhosphorylation and total protein levels of Aurora Kinases increased in TNBC cells after chemotherapy treatment.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eA:\u003c/strong\u003e IBanalysis of phosphorylation and total protein levels of Aurora Kinases in indicated cells after Paclitaxel treatment in different concentrations.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eB:\u003c/strong\u003e RPPA analysis of the alterations of Phosphorylation levels and total protein levels in TNBC cells after chemotherapy treatment.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eC-D:\u003c/strong\u003e IB analysis of indicated protein in indicated TNBC cells treated with Paclitaxel (\u003cstrong\u003eC\u003c/strong\u003e) or Docetaxel (\u003cstrong\u003eD\u003c/strong\u003e) in a concentration course.\u003c/p\u003e","description":"","filename":"Figure4.png","url":"https://assets-eu.researchsquare.com/files/rs-4889272/v1/24f12b28d30492c7a299e76e.png"},{"id":66657959,"identity":"0783da4a-354b-4a05-8e77-17d0c07ac1e4","added_by":"auto","created_at":"2024-10-15 08:24:50","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":1975869,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eAurora Kinases were upregulated by chemotherapy on post-transcription level.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eA:\u003c/strong\u003e IB analysis of indicated TNBC cells treated with Paclitaxel (1 μM) in a time-dependent course.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eB-C:\u003c/strong\u003e RT-PCR analysis of the mRNA levels of Aurora Kinases in TNBC cells treated with chemotherapy treatment.\u003c/p\u003e","description":"","filename":"Figure5.png","url":"https://assets-eu.researchsquare.com/files/rs-4889272/v1/8ace72740f5e2c9cdeb2b37b.png"},{"id":66657966,"identity":"8ee0abfd-6842-4582-8b3d-da4a0f65e463","added_by":"auto","created_at":"2024-10-15 08:24:50","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":4269276,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eAurora Kinases protein stability was increased by Paclitaxel treatment in TNBC cells.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eA-B:\u003c/strong\u003e IB analysis of indicated protein in MDA-MB-436 cells (\u003cstrong\u003eA\u003c/strong\u003e) and BT549 cells (\u003cstrong\u003eB\u003c/strong\u003e) treated with 50μg/mL protein synthesis inhibitor cycloheximide (CHX) with or without 30nM or 300nM Paclitaxel for indicated time course.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eC-D:\u003c/strong\u003e IB analysis of indicated protein in BT549 cells treated with indicated compounds.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eE: \u003c/strong\u003eIB analysis of HA-tagged AURKB or HA-tagged AURKB-T232A protein expression in 293T cells after treatment with Paclitaxel at 300nM for indicated time course.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eF: \u003c/strong\u003eIB analysis of HA-tagged AURKB or HA-tagged AURKB-T232A protein expression in 293T cells after treatment with Paclitaxel at indicated dose for 24hr.\u003c/p\u003e","description":"","filename":"Figure6.png","url":"https://assets-eu.researchsquare.com/files/rs-4889272/v1/3917e5bba768241db85e5704.png"},{"id":66658635,"identity":"a8f785d7-765f-4db5-9442-e25e46cfb327","added_by":"auto","created_at":"2024-10-15 08:32:50","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":12249650,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eAurora Kinases inhibition or degradation enhance Paclitaxel treatment in TNBC cells.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eA:\u003c/strong\u003eColony Formation assay analysis of HCC1806 TNBC cells treated with chemotherapy Paclitaxel alone or in combination with indicated compounds in indicated concentration.\u003c/p\u003e","description":"","filename":"Figure7.png","url":"https://assets-eu.researchsquare.com/files/rs-4889272/v1/e88785445b2971efa4de98ae.png"},{"id":74858328,"identity":"0e185e0f-8bfe-4eb5-bd14-0ee9211a44f6","added_by":"auto","created_at":"2025-01-27 16:08:04","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":84222979,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4889272/v1/c65d1669-1627-41d0-b41e-cbd61aa8b48a.pdf"},{"id":66657957,"identity":"178123b0-8c71-48d4-acad-189f8d018f28","added_by":"auto","created_at":"2024-10-15 08:24:50","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":5677243,"visible":true,"origin":"","legend":"","description":"","filename":"29JiaXuAliCemKucukdagliA.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-4889272/v1/1d68ac45de5834bb117b593b.xlsx"},{"id":66658632,"identity":"95d5807b-8a47-4555-a6c4-e4d25b3387e9","added_by":"auto","created_at":"2024-10-15 08:32:50","extension":"xlsx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":5676952,"visible":true,"origin":"","legend":"","description":"","filename":"29JiaXuAliCemKucukdagliB.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-4889272/v1/6bf4f0348fe1c56e15b13dd2.xlsx"},{"id":66660043,"identity":"d5accf8a-2d13-4668-8833-c43580af2b1c","added_by":"auto","created_at":"2024-10-15 08:40:50","extension":"jpg","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":8216140,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupplement Figure 1. Expression of AURKA and AURKB in AA and EA TNBC patients.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eA:\u003c/strong\u003eMitotic count in AA and EA TNBC patient with different chemotherapy outcomes.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eB-C:\u003c/strong\u003e The expression of AURKA(\u003cstrong\u003eB\u003c/strong\u003e) and AURKB(\u003cstrong\u003eC\u003c/strong\u003e) in normal breast tissue and breast tumor from TCGA dataset.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eD:\u003c/strong\u003e The expression of AURKA in normal breast tissue and TNBC tumors between AA and EA TNBC patients.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eE:\u003c/strong\u003e The H-score of AURKA IHC staining in patients with different chemotherapy outcomes including pathological complete response(pCR) and resident disease (RD).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eF:\u003c/strong\u003e H-score of AURKA IHC staining in AA and EA TNBC patients with different chemotherapy outcomes.\u003c/p\u003e\n\u003cp\u003eData are presented as the medians and SD as determined with an independent samples t-test or a Mann–Whitney U test.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eG:\u003c/strong\u003e IB analysis of Aurora Kinases expression in TNBC cells treated with Cisplatin, Gemcitabine, or Irinotecan chemotherapy.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eH:\u003c/strong\u003eRPPA analysis of TNBC cells treated with Paclitaxel chemotherapy (Full Heatmap).\u003c/p\u003e","description":"","filename":"SupplementaryFigure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4889272/v1/ed128a1c48011d7677ef34ae.jpg"},{"id":66657962,"identity":"ca19fbe5-ea0b-4e32-bf89-3e9cc74413ca","added_by":"auto","created_at":"2024-10-15 08:24:50","extension":"jpg","order_by":4,"title":"","display":"","copyAsset":false,"role":"supplement","size":1367417,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupplement Figure 2. Aurora Kinases expression in different subtypes of TNBC.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eA.\u003c/strong\u003e Percentage of CK5/6 positive case (Left) and AR positive case (Right) in TNBC chemotherapy pCR and RD group. Data are presented as the percentage of cases as determined with a Chi-square test.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eB.\u003c/strong\u003eAURKA expression in African America TNBC patients with positive AR expression or negative AR expression. Data is presented as the medians and standard deviation (SD) as determined with a Mann–Whitney U test.\u003c/p\u003e","description":"","filename":"SupplementaryFigure2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4889272/v1/66f3239d3720a6865e8b57a4.jpg"},{"id":66657964,"identity":"61c586fd-ad54-4344-9c50-97e9dadacf0e","added_by":"auto","created_at":"2024-10-15 08:24:50","extension":"pdf","order_by":5,"title":"","display":"","copyAsset":false,"role":"supplement","size":1092885,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementaryfileoriginalfilm.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4889272/v1/9dd7060748eb9a19c4ccdc5b.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Proteomic Profiling Identifies Upregulation of Aurora Kinases Causing Resistance to Taxane-type Chemotherapy in Triple Negative Breast Cancer","fulltext":[{"header":"Introduction","content":"\u003cp\u003eTriple-Negative Breast Cancer (TNBC) is one of the subtypes of breast cancer without expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), counting for around 15\u0026ndash;20% of all breast cancers \u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e,\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e. TNBC is associated with poor long-term outcomes compared to other breast cancer subtypes \u003csup\u003e\u003cspan additionalcitationids=\"CR4 CR5\" citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e. It remains the most challenging subtype to treat because of its aggressive phenotype and limited treatment options. TNBC is insensitive to endocrine and HER2-targeted therapy. It also lacks target therapy strategies probably due to the heterogenous genetic mutation burdens \u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e. TNBC has been well studied by multiple omics analysis, and it was suggested to be characterized into four potential subgroups based on their genomic profiling, including two basal-like (BL1, BL2), a mesenchymal (M) and a luminal androgen receptor (LAR) subtype \u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e. However, the genomics data fail to identify a useful treatment strategy for all subtypes of TNBC. Therefore, chemotherapy and anti-PD-L1 immunotherapy remain the mainstay of treatment \u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eIt is well known that TNBC is a chemosensitive disease and adjuvant chemotherapy is generally recommended for TNBC patients with stage I (T\u0026thinsp;\u0026gt;\u0026thinsp;1cm)-III disease \u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e. The common chemotherapies for TNBC given to patients include Anthracycline agents such as Adriamycin (Doxorubicin), alkylating agents such as Carboplatin, and Taxane agents such as Paclitaxel \u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. Fluorouracil (5FU) may be given as well. A combination of drugs, or a \u0026ldquo;chemo cocktail,\u0026rdquo; is often given to patients and achieves the most favorable tumor inhibition effect. However, not all TNBC patients respond to chemotherapy, suggesting that TNBC is a complicated disease \u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e,\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e. Pathologic complete response (pCR) so far remains a validated surrogate biomarker for the prediction of long-term clinical benefit with neoadjuvant chemotherapy because it has been shown to correlate with improved overall survival \u003csup\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e. Identifying biomarkers to further predict and subdivide TNBC patients with distinct outcomes is of great importance. Three randomized trials evaluated the addition of neoadjuvant carboplatin for the treatment of triple-negative breast cancer: the phase II CALGB 40603; the phase II GeparSixto; and the phase III BrighTNess\u003csup\u003e\u003cspan additionalcitationids=\"CR15\" citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e. These studies demonstrate that the addition of neoadjuvant carboplatin to anthracycline/taxane chemotherapy improves pCR in unselected TNBC. The overall pCR rate was improved to 55% compared to single-agent chemotherapy \u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e. However, higher pathologic complete response rates did not translate to improved event-free survival and this combination strategy also comes with a cost of a significant increase in toxicity. Thus, improved therapeutic approaches with different strategies are desired for TNBC.\u003c/p\u003e \u003cp\u003eAfrican-American (AA) women have a high prevalence of TNBC with worse clinical outcomes than European-American (EA) women \u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. Studies found two-fold higher population-based incidence rates of TNBC in AA compared with EA women in all age categories, including the 2015 Annual Report to the Nation on the Status of Cancer \u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e, documenting TNBC incidence rates of AA women (27.2 per 100,000) vs. EA women (14.4 per 100,000) respectively. Racial differences in biological factors, such as tumor heterogeneity, population genetics, somatic genomic mutations, and gene expression alterations in AA breast tumors could cause disparities in TNBC \u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. Meanwhile, a large number of non-biologic factors, including socioeconomic deprivation adversities associated with poverty, may adversely contribute to the aggression of TNBC biology in AA women \u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. Moreover, compared to EA women, AA women but not Hispanic or Asian women, have significantly lower rates of pCR for TNBC tumors after receiving neoadjuvant chemotherapy (AA 37% vs. EA 43%, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001) \u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e. The five-year breast cancer-specific survival rates are also significantly lower in AA patients (78.9%) compared with EA patients (88.6%)\u003csup\u003e21\u003c/sup\u003e. However, the cause of the higher mortality rate and lower response rate to neoadjuvant chemotherapy for AA TNBC patients is largely unknown.\u003c/p\u003e \u003cp\u003eAurora kinase A (AURKA) and Aurora kinase B (AURKB) are members of the Aurora kinase subfamily of conserved serine/threonine kinases \u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e. AURKA plays a critical role in centrosome duplication and maturation, while AURKB plays a crucial role in cell division as the catalytic protein of the chromosomal passenger complex (CPC) during mitosis by regulating chromosomal alignment, segregation, and cytokinesis \u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e. Deregulation of Aurora kinases leads to impairment of mitotic spindle checkpoints causing abnormal spindle assembly and chromosome segregation \u003csup\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e. Overexpression of AURKA and AURKB has been reported in various types of cancer, including TNBC\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e. Inhibition of Aurora Kinases seems to potentiate the effect of chemotherapy \u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e, however, the mechanism of how Aurora kinases contribute to the response of chemotherapy is still elusive and the role of Aurora Kinase in TNBC disparity has not been fully explored.\u003c/p\u003e \u003cp\u003eIn our study, we tried to explore the expression of Aurora Kinases in patient samples from our UAB TNBC cohort, which included AA and EA patients. The expression of AURKA and AURKB was explored by immunohistochemistry (IHC) to find if these mitosis-related proteins are associated with race, subtypes of TNBC, prognosis and chemotherapy response. Resection and biopsy samples were matched to analyze the level of Aurora Kinases and clinicopathologic features before and after chemotherapy. We also investigated the molecular mechanism underlying how Aurora kinase confers chemotherapy resistance in TNBC cells.\u003c/p\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eClinicopathologic Characteristics of UAB TNBC Cohort\u003c/h2\u003e \u003cp\u003eTo understand whether the biological risk factors driving the disparities result in the aggressive TNBC subtypes, a total of 54 matched TNBC patient samples (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e) diagnosed at UAB hospital were evaluated, including 28 AA patients (51.9%) and 26 EA patients (48.1%). To investigate the mechanism of racial disparities of genetic contribution to chemotherapy resistance in TNBC, we divided these patients into two groups based on their pathological evaluation: pathological complete response (pCR, n\u0026thinsp;=\u0026thinsp;28) and residual disease (RD, n\u0026thinsp;=\u0026thinsp;26) (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). After Neoadjuvant chemotherapy treatment, 28 patients (15 AA patients and 13 EA patients) showed a pathologic complete response (pCR), while 26 patients (13 AA patients and 13 EA patients) still had residual disease (RD). The patient\u0026rsquo;s mean age at diagnosis was 55.5 y for the pCR group and 58.0 y for the RD group. A summary of patients\u0026rsquo; clinicopathologic characteristics post neoadjuvant chemotherapy containing pT stage, pN stage, pM stage, histological grade, and lymphovascular invasion (LVI) are depicted in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eClinicopathological features for TNBC samples of UAB cohort\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCharacteristic\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eResidual disease(n\u0026thinsp;=\u0026thinsp;26)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePathologic complete response (n\u0026thinsp;=\u0026thinsp;28)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge (mean, y)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e58.0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e55.5\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRace\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAfrican America\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e13/26(50.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e15/28(53.6%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEuropean America\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e13/26(50.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e13/28(46.4%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHistological Grade\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1/26(3.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5/28(17.9%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e25/26(96.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e23/28(82.1%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eT stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eT0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0(0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e26/28(92.9%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0(0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2/28(7.1%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eT1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e15/26(57.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0(0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eT2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e8/26(30.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0(0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eT3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3/26(11.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0(0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eN stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eN0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e20/26(76.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e26/28(92.9%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eN1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3/26(11.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2/28(7.1%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eN2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1/26(3.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0(0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eN3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2/26(7.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0(0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eM stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eM0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e23/26(88.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e24/28(85.7%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eM1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3/26(11.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4/28(14.3%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLVI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePresent\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4/26(15.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0(0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAbsent\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e22/26(84.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e100(100%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003eLVI\u0026thinsp;=\u0026thinsp;Lymphovascular invasion\u003c/p\u003e \u003cp\u003e*Histological grade, TNM stage and LVI was scored in resection samples.\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eThe disparity of mitotic count in AA and EA patients\u003c/h2\u003e \u003cp\u003eMost TNBCs exhibit marked nuclear pleomorphism and increased mitoses \u003csup\u003e\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e. Tumor cell proliferation is a critical component of the Nottingham grading system. It is one of the most powerful prognostic factors\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e, and a well-recognized histo-morphologic predictor of outcome in breast cancer\u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e. In this study, we counted the mitotic activity index (MAI) \u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e using the Nottingham combined histologic grading system and compared the mitotic score in AAs to that in EAs. In our UAB TNBC cohort, 40 (74.1%) cases identified a mitotic count score of 3. The number of cases in each mitotic count score group (1, 2, and 3) was similar in AA and EA patients, but the mean count of mitosis in AA was slightly higher (p\u0026thinsp;=\u0026thinsp;0.104) than in EA patients (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA). However, there is no statistically significant difference between EA and AAs in the pCR and RD groups, respectively (Supplementary Fig.\u0026nbsp;1A). We further subdivided the patients into \u0026ldquo;mitosis high\u0026rdquo; (count\u0026thinsp;\u0026ge;\u0026thinsp;60), and \u0026ldquo;mitosis low\u0026rdquo; (count\u0026thinsp;\u0026lt;\u0026thinsp;60) groups based on the mitosis counts. Chi-square analysis showed that there is a significant association (p\u0026thinsp;=\u0026thinsp;0.025, \u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\:{x}^{2}\\)\u003c/span\u003e\u003c/span\u003e=5.934) between AA patients and \u0026ldquo;mitosis-high\u0026rdquo; (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB), suggesting AA TNBC patients have higher number of proliferative cancer cells.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eDisparity of AURKB expression in AA and EA in biopsy sample\u003c/b\u003e \u003c/p\u003e \u003cp\u003eAs the mitotic score is disproportionally distributed into EA and AA groups, we aim to look at the expression level of those genes regulating the mitosis process and cell division, including Aurora Kinases, and their pattern or distribution in different ethnic groups. We evaluated the expression of AURKA and AURKB using immunohistochemical staining in 54 TNBC cases along with 29 tumor-adjacent normal breast tissue samples (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eI). H-Score semi-quantitative analysis of IHC staining showed that AURKA and AURKB were absent or minimally expressed in normal breast tissues adjacent to the tumor (NAT). Statistics analysis showed that AURKA (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) and AURKB (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) expression levels were significantly higher in TNBC tumors compared to NAT, with the average H-score for AURKA and AURKB in TNBC as 37.7 and 86.7, respectively (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eC and \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eD). The result is consistent with the report in the TCGA breast cancer dataset (Supplementary Figs.\u0026nbsp;1B and 1C). Interestingly, the AURKB expression level was much higher in AA patients (Mean H score\u0026thinsp;=\u0026thinsp;93.59) than in EA patients (Mean H score\u0026thinsp;=\u0026thinsp;79.06) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eE), and the percentage of AURKB high expression cases (H score \u0026ge; 150) in AA was significantly more than that in EA (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eF, P\u0026thinsp;=\u0026thinsp;0.026, \u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\:{x}^{2}\\)\u003c/span\u003e\u003c/span\u003e=4.969). These findings are consistent with the analysis of the publicly available TCGA Breast Cancer dataset and IHC staining pattern of FFPE TNBC tissue samples in the Georgia cohort\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e. On the other hand, although the AURKA expression level was higher in the tumor area than in NAT, no significant difference between EA and AA and no significant difference between pCR and RD groups was identified (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eC and Supplementary Fig.\u0026nbsp;1D-1F).\u003c/p\u003e \u003cp\u003eCompared with pCR patients, patients with RD post-neoadjuvant treatment tended to show higher H-scores for AURKB in biopsy (pre-treatment) specimens, although the difference was not statistically significant (p\u0026thinsp;=\u0026thinsp;0.218, Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eG). Further analysis revealed that RD EA patients had a significantly higher expression of AURKB in pre-treatment biopsy specimens than pCR EA patients (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eH, p\u0026thinsp;=\u0026thinsp;0.039), suggesting a correlation between the AURKB protein expression levels and chemotherapy resistance in TNBC. Further analysis revealed a linear correlation between the H-scores of AURKA, AURKB, and mitotic count (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA-\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eC). In addition, AURKB-high patients presented higher mitotic count in the pre-treatment biopsy sample than AURKB-low patients (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eD, P\u0026thinsp;=\u0026thinsp;0.003), suggesting AURKB expression is highly correlated with mitosis and tumor cell proliferation in TNBC.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eAURKA and AURKB Expression in different TNBC subtypes\u003c/h2\u003e \u003cp\u003eTNBC could be further divided into four molecular subgroups by comprehensive genomics profiling: luminal androgen receptor (LAR), mesenchymal (M), basal-like type 1(BL1), and basal-like type 2(BL2)\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e,\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e. IHC has been used as an alternative way for TNBC subclassification to reduce costs and enhance its compatibility with clinical practice\u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e,\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e. Therefore, we used CK5/6 to identify the basal-like group and AR for the LAR group and tried to explore the cancer proliferation index in different TNBC subtypes. In our cohort, 20/54 (37%) cases showed CK5/6 positivity and 18/54 (33.3%) cases showed AR-positivity. Among positive cases, 6 cases expressed both CK5/6 and AR. For the remaining 22 patients, the expression of these two markers was both negative. However, we did not observe any correlation between chemotherapy resistance and any subtypes of TNBC, such as the CK5/6\u0026thinsp;+\u0026thinsp;basal group or AR\u0026thinsp;+\u0026thinsp;LAR group (Supplementary Fig.\u0026nbsp;2A). Interestingly, we found that AURKA expression was higher in AR-positive cases than AR-negative cases only in AA patients among the different TNBC subtypes (Supplementary Fig.\u0026nbsp;2B, P\u0026thinsp;=\u0026thinsp;0.009). Overall, the mitotic score, AURKA expression, and AURKB expression did not differ among these TNBC subgroups.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eAURKA and AURKB overexpression confers TNBC cells resistant to Chemotherapy treatment\u003c/h2\u003e \u003cp\u003eSince we found that AURKB is highly correlated with chemotherapy resistance in TNBC, we intend to examine whether AURKB upregulation causes chemotherapy resistance in TNBC cell lines. We analyzed their expression level in a panel of 13 primary TNBC cell lines (ATCC TNBC panel) based on the RPPA data from Cancer Cell Line Encyclopedia (CCLE) and confirmed by western blot analysis. Based on the race group, we generally divided these TNBC cells into two groups: AA TNBC cells (MDA-MB-468, HCC1806, HCC70, HCC2157, and MDA-MB-157) and EA TNBC cells (MDA-MB-453, BT20, HCC1395, Hs578T, HCC1187, DU4475, and HCC1937) (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA). There was a clear trend that AA TNBC cells had higher levels of AURKB than those in the EA TNBC group, while PLK1 or AURKA expression was not quite different between these two groups. Next, we overexpressed AURKB in BT549 and Hs578T cells or AURKA in HCC1143 and HCC1937 TNBC cells and found that AURKB or AURKA overexpression in TNBC cells renders them more resistant to paclitaxel treatment (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB). In addition, AURKB overexpression in BT549 cells prevented paclitaxel treatment-induced cell death as evidenced by reduced apoptosis marker cleaved-caspase 3 by AURKB overexpression (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA), suggesting upregulation of AURKB expression in TNBC cells could be a strategy for the cancer cells escaping from chemotherapy treatment and mediating the chemo-resistance in TNBC.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eTaxanes-type chemotherapy treatment upregulates Aurora Kinases expression.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eSince we found that Aurora Kinases are critical to chemotherapy response, we want to see how these genes change after chemotherapy treatment. It has been reported that EMT could render chemoresistance in TNBC\u003csup\u003e\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u003c/sup\u003e, but we did not observe the EMT markers (E-cadherin and Vimentin) changed in AURKB overexpressing BT549 cells compared to parental BT549 cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA). Thus, to probe the molecular basis for differential response to neoadjuvant chemotherapy for TNBC, we performed a comprehensive Reverse Phase Protein Array (RPPA) on MDA-MB-468 cells and MDA-MB-231 cells treated with Docetaxel and Paclitaxel (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB and Supplementary Fig.\u0026nbsp;1H). Interestingly, we found only a short list of protein changes after chemotherapy. Among them, the most significant changes in protein are phosphor-AURKA/B/C, phosphor-H3(S10), AURKA, AURKB, and PLK1, which fall into the mitotic kinase group (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB and Supplementary Fig.\u0026nbsp;1H). Phosphorylation of the Serine 10 site on Histone H3 is a hallmark of mitosis, and it is primarily caused by AURKB\u003csup\u003e\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e,\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u003c/sup\u003e and upregulated by Paclitaxel and Docetaxel treatment. By western blot analysis, we have confirmed this finding in multiple TNBC cells, including MDA-MB-468 cells and MDA-MB-231 cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC-\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eD). Compounds targeting microtubule depolymerization (Docetaxel and Paclitaxel, Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC and \u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eD) indeed upregulated AURKB and AURKA expression. However, the platinum compounds (Cisplatin and Carboplatin), antimetabolite compounds (Gemcitabine), and compounds that arrest DNA replication (Epirubicin and Doxorubicin) did not show the same trend (Supplementary Fig.\u0026nbsp;1G). These data suggest that the upregulation of AURKA and AURKB is unique to the specific type of chemotherapies. In addition, the upregulation of AURKA and AURKB happened in a short time, as soon as 12 hours of paclitaxel treatment (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eA). RT-PCR analysis of AURKA and AURKB mRNA levels after Docetaxel and Paclitaxel treatment showed no significant change (\u0026lt;\u0026thinsp;2 fold) in the mRNA level in the majority of cell lines (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eB-\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eC), suggesting a post-transcription level molecular mechanism regulates the upregulation of AURKA and AURKB protein.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eChemotherapy treatment upregulated AURKA and AURKB by promoting their protein stability.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eWe next accessed the protein stability of Aurora Kinases in MDA-MB-436 cells treated with 50 \u0026micro;g/mL protein synthesis inhibitor cycloheximide (CHX) with or without Paclitaxel for the indicated time course. As shown in Figs.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eA and \u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eB, compared with the co-treatment of CHX and Paclitaxel, the protein level of AURKB and AURKA decreased more significantly with CHX treatment alone, indicating Paclitaxel extended the lifetime of Aurora Kinases protein and increased the protein stability of AURKB in MDA-MB-436 cells and BT549 cells. In contrast, the protein stability of PLK1 and AURKA increased after paclitaxel treatment in both cell lines but was not as significant as the increase of AURKB. Since we found that Paclitaxel treatment also upregulated Phosphorylation of AURKA (T288) and AURKB (T232) from our RPPA data (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB and Supplementary Fig.\u0026nbsp;1H) and PhosphoSitePlus\u0026reg; database (Cell Signaling Technology)\u003csup\u003e\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e,\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u003c/sup\u003e, we hypothesis that Paclitaxel treatment promotes AURKB protein stability via upregulating the phosphorylation of AURKB/AURKA at T232/T288 site respectively. To this end, we treated AURKB-T232 phosphorylation inhibitor AZD1152 (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eC) or AURKA-T288 kinase inhibitor Alisertib (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eD) to inhibit their phosphorylation and activity as shown by the decrease of downstream cascade phosphor-H3-S10, and it also blocked the paclitaxel-induced stability and accumulation of AURKA and AURKB protein in BT549 cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eC and \u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eD), suggesting that phosphorylation of AURKB/AURKA is critical to the protein stability of AURKB/AURKA caused by Paclitaxel treatment. To further test if phosphorylation of the T232 site is the key site for protein stability of AURKB, we have mutated the Threonine 232 site into Alanine (T232A) on HA-tagged AURKB and HA-tagged AURKB-T73A (non-phosphorylatable mutant) vector system. After we stable transfected them into 293T cells and treated with Paclitaxel for 0, 4, 12, 18, and 24 hrs., we found that Paclitaxel treatment increased HA-AURKB expression since 12 hr. time point but not HA-AURKB-T232A expression (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eE). In addition, we also performed a dose course of paclitaxel treatment and found Paclitaxel treatment increased HA-AURKB expression at a low concentration of 300nM but not HA-AURKB-T232A expression (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eF). Thus, our data suggest that Taxanes-type and Anthracyclines-type chemotherapy treatment could upregulate the phosphorylation of AURKA/B and increase their protein stability.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eAurora Kinases inhibition or degradation enhances Paclitaxel treatment in TNBC cells\u003c/h2\u003e \u003cp\u003eSince we found that Paclitaxel treatment could upregulate the phosphorylation of AURKA/B and increase their protein stability, we hypothesize that Aurora Kinases inhibition or degradation could enhance Paclitaxel treatment in TNBC cells. To this end, we treated HCC1806 TNBC cells with Paclitaxel, Paclitaxel plus AZD1152 (1 \u0026micro;M), Paclitaxel plus Alisertib (1 \u0026micro;M), Paclitaxel plus AURKA PROTAC degrader JB170 (1 \u0026micro;M), or Paclitaxel plus Aurora Kinases pan inhibitor AMG900 (1 \u0026micro;M), and we found that AZD1152, Alisertib and JB170 significantly enhanced the Paclitaxel treatment at very low concentration of 1 nM, which could greatly potentially benefit the patient with minimal side effect or toxicity of chemotherapy (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eA). However, the AMG900 effect is not as good as the other three compounds. These data indicated that Aurora Kinases inhibition or degradation indeed enhances Paclitaxel treatment in TNBC cells.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eTNBC is the most aggressive breast cancer subtype with poor survival outcomes, and it also lacks reliable predictive biomarkers and therapeutic targets. African American (AA) women with TNBC generally have poorer neoadjuvant chemotherapy response and worse survival rates compared to European American (EA) women\u003csup\u003e\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e\u003c/sup\u003e. Thus, understanding the molecular mechanism underlying chemotherapy response disparity is crucial. The racial disparities in breast cancer come from both socioeconomic determinants and biological molecular alterations. Previous studies have found that AA patients with TNBC showed higher cell proliferation than their EA counterparts, which is characterized by enriched mitotic count and increased Ki-67 expression\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e,\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e\u003c/sup\u003e. Tumor cells with a high mitotic index are usually associated with shorter survival and an increased risk of distant recurrence\u003csup\u003e\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e\u003c/sup\u003e. Our study demonstrates that higher mitotic counts were more frequently observed in AA patients, and AURKB expression in AA patients is higher than in EA patients in TNBC, suggesting the expression of AURKB could contribute to the cancer disparity in TNBC. In addition, the high expression of AURKB is also highly associated with an aggressive feature with a high mitotic rate and high expression of AURKA. This finding is consistent with a previous report in Georgia TNBC cohort\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e and the publicly available TCGA Breast Cancer dataset. Both AURKA and AURKB expression were elevated in the tumor cells compared to NAT. However, our study did not find a significant difference in AURKA expression between AA and EA patients. A possible explanation might be that these two proteins play redundant roles in the same cellular process but have distinct expression patterns and regulations.\u003c/p\u003e \u003cp\u003eThe expression of AURKB is higher in EA patients who had residual disease after neoadjuvant chemotherapy than those who turned to pathological complete response. The results suggest that the AURKB expression status could serve as a predictor for post-neoadjuvant chemotherapy outcomes for TNBC patients and a valuable biomarker for choosing the right patients who may respond to chemotherapy. However, we did not find a significant correlation between AURKB expression with chemotherapy outcomes in AA TNBC patients. This could be related to the uniformly high expression of AURKB in the pre-treatment biopsy samples of both the residual tumor group and the complete response group in AA patients.\u003c/p\u003e \u003cp\u003eThe four subtypes of TNBC may respond to different types of therapeutical strategies, and BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines were found to respond to cisplatin preferentially\u003csup\u003e\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e\u003c/sup\u003e. We have evaluated the correlation of MAI score, Aurora Kinases, and PLK1 expression level within subtypes of TNBC and race/ethnicity status. Interestingly, elevated expression levels of AURKA were observed in AR-positive AA patients compared to the AR-negative group, suggesting AURKA expression is highly correlated with AR expression. Interestingly, previous studies in prostate cancer have also indicated a reciprocal regulation between these two proteins that upregulated the expression of AURKA in prostate cancer cells exhibiting high AR expression levels\u003csup\u003e\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e\u003c/sup\u003e. Further investigation is warranted to determine whether AURKA could serve as a therapeutic target for AR-positive TNBC. Additionally, it is noteworthy that our results revealed 6 cases exhibiting concurrent positive expression of AR and CK5/6, suggesting IHC methods remain incapable of substituting molecular detection techniques for effective molecular subtyping of TNBC. Thus, it is critical to develop a more effective IHC biomarker for the clinical diagnosis of TNBC subtypes.\u003c/p\u003e \u003cp\u003ePrevious reports using combined next-generation sequencing and digital RNA expression analysis identified several molecular pathway activations on the residual disease of 74 TNBCs after neoadjuvant chemotherapy\u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u003c/sup\u003e. Cell-cycle alterations, including amplification of CDK4/6, AURKA, and loss of CDKN2A, CDKN2B, or RB1, were observed in this study\u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u003c/sup\u003e. Our result clearly showed that the mRNA levels of AURKA and AURKB were not significantly changed in TNBC cells treated with chemotherapy, but protein and phosphorylation levels were dramatically altered, as shown by RPPA array and western blot, suggesting RPPA array, proteomics, and IHC analysis could be more accurate than next generation sequencing genomics profiling to dissect the molecular mechanism of chemotherapy resistance in TNBC. Previous Quantitative phosphoproteomics have identified four potential phosphorylation sites on AURKB- p-T232, p-T236, p-S313, and p-S331 after Taxol treatment which is similar to paclitaxel treatment in PhosphoSitePlus\u0026reg; database powered by Cell Signaling Technology\u003csup\u003e\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003e. We identified phosphorylation on T232 site was critical for Paclitaxel induced phosphorylation and protein stability of AURKB, leading to a combinatory therapy strategy with Aurora Kinases inhibition and chemotherapy. Chemotherapy like paclitaxel or Doxorubicin usually leads to cell cycle arrest or apoptosis \u003csup\u003e\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e. Paclitaxel is an anti-mitotic agent that binds to microtubules and stabilizes them against depolymerization, and deacetylation of a-tubulin induces microtubule depolymerization and results in microtubule instability \u003csup\u003e\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e\u003c/sup\u003e and diminishes the effect of chemotherapy treatment-induced microtubule stability. Our study has showed that AURKB overexpression attenuates the apoptosis effect caused by Paclitaxel treatment, and inhibition of both Aurora A and B kinases have been shown to significantly increase apoptosis and reduce proliferation in TNBC cells\u003csup\u003e\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e,\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e\u003c/sup\u003e. Thus, Aurora Kinases could regulate chemotherapy resistance through destabilizing microtubules, and it may shed light on the mechanism underlying the chemotherapy resistance and worth further investigation.\u003c/p\u003e"},{"header":"Materials and Methods","content":"\u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003ePatient Cohort\u003c/h2\u003e \u003cp\u003eWe retrospectively identified 54 TNBC patients who underwent neoadjuvant chemotherapy at the University of Alabama at Birmingham (UAB) Hospital between 2011 and 2023, with available matched formalin-fixed paraffin-embedded core needle biopsy samples and surgical resection samples.\u003c/p\u003e \u003cp\u003eTNBC was defined as breast cancer that was negative for ER (\u0026lt;\u0026thinsp;1%), PR (\u0026lt;\u0026thinsp;1%), and negative for HER2 overexpression (score 0, 1 and 2) by IHC and HER2 amplification by silver-enhanced in situ hybridization. Clinicopathological characteristics, including treatment and prognosis information, were collected from the electronic medical records. This study was approved by the Institutional Review Board of UAB (IRB-300011620). Due to the retrospective nature of the study, Institutional Review Board waived the need of obtaining informed consent. All experiments were performed in accordance with relevant guidelines and regulations.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eHistologic Evaluation\u003c/h2\u003e \u003cp\u003eHematoxylin and eosin (H\u0026amp;E)-stained slides from all the cases were reviewed by two experienced pathologists. World Health Organization classification and Nottingham combined histologic grading system were used to identify tumor histologic subtypes and grades. In all biopsy slides, mitoses were counted in 10 consecutive high-power fields (HPFs). Based on a microscope field diameter of 0.50 mm, counts of 0 to \u0026le;\u0026thinsp;7, 8\u0026ndash;14 and \u0026ge;\u0026thinsp;15 mitoses per 10 HPFs corresponded to mitotic scores of 1, 2, and 3, respectively as previously described\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e. The case was considered \u0026ldquo;high-mitosis\u0026rdquo; when the mitotic count was equal to or greater than 60.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eImmunohistochemical Staining and Evaluation\u003c/h2\u003e \u003cp\u003eIHC staining was performed on formalin-fixed, paraffin-embedded tumor tissue samples retrieved from the Department of Pathology at UAB Hospital. The slides were baked on a slide warmer for 1.5h at 70℃. After deparaffinization and rehydrated, the heat-induced antigen retrieval method was performed with citrate buffer (pH 6.0, Abcam, ab93678) for 30min. The slides were then incubated with primary antibody at 4\u0026deg;C overnight. The following antibodies and dilutions were used: AURKA (#91590 from Cell Signaling Technology, Inc., USA, 1:100), AURKB (NBP2-61493, Novus Biologicals, LLC, 1:100), cytokeratin 5/6 (M7237, Agilent Technologies, USA,1:50), androgen receptor (200R-17, Sigma-Aldrich, USA, 1:100). Goat anti-Rabbit horseradish peroxidase-conjugated antibody (31460, Thermo Scientific, USA, 1:100) and goat anti-mouse horseradish peroxidase-conjugated antibody (31430, Thermo Scientific, USA, 1:100) was used as the secondary antibody. After incubated in DAB (34000, Thermo scientific, USA), all slides were counterstained with Mayer\u0026rsquo;s Haematoxylin applied for 2 min.\u003c/p\u003e \u003cp\u003eAURKA and AURKB expression was evaluated by the H-score system. Any level of cytoplasmic or nuclear staining of AURKA and nuclear staining of AURKB was considered positive. Lymph node tissue was used as positive control. The intensity was classified into four categories (none, 0; weak, 1+; moderate, 2+; and strong, 3+). The percentage of positive tumor cells was estimated. H-scores were calculated by multiplying the percentage of positive tumor cells by the corresponding intensity of AURKA/AURKB expression, with total scores ranging from 0 to 300. The case was considered \u0026ldquo;AURKA-high\u0026rdquo; when the H-score of AURKA was higher than 100. \u0026ldquo;AURKB-high\u0026rdquo; was considered when the H-score of AURKB was equal or greater than 150.\u003c/p\u003e \u003cp\u003eThe percentage of positive tumor cells of androgen receptor (AR) and cytokeratin 5/6 (CK5/6) was evaluated in nuclear and membrane, respectively. When positive staining show in \u0026gt;\u0026thinsp;1% of tumor cells, the case was considered positive.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eStatistical Analysis\u003c/h2\u003e \u003cp\u003eAll data were analyzed using SPSS version 25.0 software for Windows (SPSS, Chicago, IL, USA) as previously described\u003csup\u003e\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e\u003c/sup\u003e. T-test and Wilcoxon signed-rank test were used to show the difference in mitotic count H-score between different groups. The chi-square test or Fisher exact test was used as appropriate to analyze the relationship between mitotic count, AURKA-high, AURKB-high, and clinical characteristics. A P value of \u0026le;\u0026thinsp;0.05 was considered statistically significant.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003eCell Culture:\u003c/h2\u003e \u003cp\u003eTNBC panel cell lines (ATCC-TCP-1001, TCP-1002, TCP-1003) including BT549, MDA-MB-468, MDA-MB-231, MDA-MB-453, MDA-MB-436, HCC1395, and HCC1806 cell lines were purchased from ATCC. Cell lines were regularly tested in the lab for mycoplasma. All cells were cultured at 37\u0026deg;C and 5% CO2. MDA-MB-468, MDA-MB-453 and MDA-MB-436 cells were cultured in 1X DMEM with 10% fetal bovine serum (Corning 35-011-CV) and 1X Penicillin/Streptomycin. Cells culture media was changed every 3\u0026ndash;4 days and cells were passaged using 0.05% or 0.25% trypsin. Corning Media includes DMEM: 10-013-CV, RPMI: 10-040-CV, 50/50 DMEM/ Ham\u0026rsquo;s F-12: 10-090-CV.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eDrug Treatments:\u003c/h2\u003e \u003cp\u003ePaclitaxel (Med Chem Express, HY-B0015), Docetaxel (Selleckchem, S1148), Doxorubicin (Selleckchem, S1208), Epirubicin (Selleckchem, S1223), Cycloheximide (CHX, Selleckchem, S7418), Alisertib (Med Chem Express, HY-10971), Barasertib (AZD1152-HQPA) (Selleckchem, S1147), JB170 (Med Chem Express, HY-141512), AMG-900 (Selleckchem, S2719), Cisplatin (Selleckchem, S1166), Gemcitabine (Selleckchem, S1714 ), Irinotecan (Selleckchem, S1198), were dissolved in DMSO at a concentration of 10 mM. Control is treatment with equal volume of DMSO. Doxorubicin: Doxorubicin hydrochloride (Sigma 44583-1MG) was dissolved in DMSO.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003eGeneration of overexpression cells:\u003c/h2\u003e \u003cp\u003eFor stable overexpression of AURKA, AURKB, AURKB(T232A) in BT549, HCC1143, HCC1937, and 293T cells, Lentiviral plasmid p7052 pHAGE-P-CMVt-N-HA-GAW-AURKB (Cat# 100142), and pHR_dSV40-Aurora A-GFP(Cat#67924) were purchased from Addgene. AURKB (T232A) mutations were made using QuickchangeII XL site directed mutagenesis kit (Agilent, Cat# 200522) as previously described\u003csup\u003e\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u003c/sup\u003e. Lentiviral plasmids were transfected as previously described\u003csup\u003e\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u003c/sup\u003e into the packaging cells 293T cells together with two other plasmids: packaging DNA (psPAX2) and envelope DNA (pMD2G) through Lipofectamine transfection. After 48 hrs transfection, viruses were collected, filtered, and used to infect TNBC cells in the presence of 8\u0026ndash;10 \u0026micro;g/mL polybrene for 24 hrs. The infected cells were selected with 4\u0026ndash;8 \u0026micro;g/mL puromycin\u003csup\u003e\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003eBRNA extraction, RT-PCR (reverse-transcription\u0026ndash;polymerase chain reaction) and quantitative real-time RT-PCR\u003c/h2\u003e \u003cp\u003eAs previously described RT-PCR method\u003csup\u003e\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e\u003c/sup\u003e, total RNA from cells was isolated using Trizol reagent (Invitrogen) and protocol was followed as per the manufacturer\u0026rsquo;s instructions. 1 \u0026micro;g of total RNA was reverse transcribed into cDNA using iScript\u0026trade; cDNA synthesis kit (Biorad) following the manufacturer\u0026rsquo;s instructions. Then, an equivalent volume (1 \u0026micro;l) of cDNA was used as a template for quantitative real-time PCR with iQ\u0026trade; SYBR Green Supermix (Biorad) and the StepOnePlus\u0026trade; (Applied Biosystems) instrument according to the manufacturer\u0026rsquo;s instructions. The names of the genes quantified and the sequences of the primers are given in the following table. The threshold cycles for specific targets were then normalized to the threshold cycles of GAPDH to calculate the relative fold-change difference\u003csup\u003e\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003eqRT-PCR primers:\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"No\" id=\"Taba\" border=\"1\"\u003e \u003ccolgroup cols=\"2\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eprimers\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003esequence\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAURKB-Forward\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5\u0026rsquo;-CAGTGGGACACCCGACATC-3\u0026rsquo;\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAURKB-Reverse\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5\u0026rsquo;-GTACACGTTTCCAAACTTGCC-3\u0026rsquo;\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAURKA-Forward\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5\u0026rsquo;-GAGGTCCAAAACGTGTTCTCG-3\u0026rsquo;\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAURKA-Reverse\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5\u0026rsquo;-ACAGGATGAGGTACACTGGTTG-3\u0026rsquo;\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGAPDH-Forward\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5\u0026rsquo;-GGAGCGAGATCCCTCCAAAAT-3\u0026rsquo;\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGAPDH-Reverse\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5\u0026rsquo;-GGCTGTTGTCATACTTCTCATGG-3\u0026rsquo;\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cdiv id=\"Sec19\" class=\"Section3\"\u003e \u003ch2\u003eImmunoblotting:\u003c/h2\u003e \u003cp\u003eImmunoblotting was performed as previously described\u003csup\u003e\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u003c/sup\u003e. Protein lysates were loaded into 4\u0026ndash;12% Bis-Tris gels and resolved by electrophoresis. Samples were then blotted on PVDF membrane (Millipore IPVH00010) using the semi-dry transfer technique (Bio-Rad). Membranes were visualized using autoradiography film (Denville E3018)\u003csup\u003e\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u003c/sup\u003e. Primary Antibodies: β-actin (Sigma #A5316), Aurora B/AIM1 (E3R8N) (CST#28711), Aurora A (D3V7T) (CST#91590), Phospho-Aurora A (Thr288)/Aurora B (Thr232)/Aurora C (Thr198) (D13A11)(CST#2914), PLK1 (208G4)(CST#2914), HA-Tag (C29F4) (CST#3724), Cleaved-Caspase 3 (CST#9664) were from Cell Signaling Technology. Secondary Antibodies: Mouse (Thermo 31430), Rabbit (Thermo 31460).\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003eColony formation assay\u003c/h2\u003e \u003cp\u003eColony formation assay was performed as previously described\u003csup\u003e\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u003c/sup\u003e. Cells were cultured for 12\u0026ndash;17 days in the presence of different compounds. Media with compound was replenished every two days. At the end of the experiment, media was aspirated, and viable cells were stained with 0.5% crystal violet dye\u003csup\u003e\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec21\" class=\"Section2\"\u003e \u003ch2\u003eReverse phase protein array (RPPA):\u003c/h2\u003e \u003cp\u003eRPPA was performed in MDACC Functional Proteomics core facility as previously described\u003csup\u003e\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e,\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e\u003c/sup\u003e. Briefly, cellular proteins were denatured by 1% SDS, serially diluted, and spotted on nitrocellulose-coated slides. Each slide was probed with a validated primary antibody plus a biotin-conjugated secondary antibody. The signal obtained was amplified using a Dako Cytomation\u0026ndash;catalyzed system and visualized by DAB colorimetric reaction. The slides were analyzed using customized Microvigene software (VigeneTech Inc., Carlisle, MA). Each dilution curve was fitted with a logistic model (\u0026ldquo;SuperCurve Fitting\u0026rdquo; developed at MDACC) and normalized by median polish. The data were further adjusted for batch effects by normalizing identical control samples in this set with an invariant control sample set and applying the adjustment to each corresponding data point. The heatmap was then generated using R version 4.1.0 with the normalized data that have also been median centered by antibodies. The data clustering was performed using Cluster 3.0 (centered by gene, followed by hierarchical clustering by gene and array using complete linkage) and TreeView\u003csup\u003e\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e,\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec22\" class=\"Section2\"\u003e \u003ch2\u003e\u003cb\u003eTCGA data analysis in the Tumor Immune Estimation Resource (TIMER) database\u003c/b\u003e:\u003c/h2\u003e \u003cp\u003eTCGA gene expression data analysis was performed in the Tumor Immune Estimation Resource (TIMER) (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://cistrome.shinyapps.io/timer/\u003c/span\u003e\u003cspan address=\"https://cistrome.shinyapps.io/timer/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) database as previously described\u003csup\u003e\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e\u003c/sup\u003e. Gene_DE module allows users to study the differential expression between tumor and adjacent normal tissues for any gene of interest across all TCGA tumors. Distributions of gene expression levels are displayed using box plots. The statistical significance computed by the Wilcoxon test is annotated by the number of stars (*: p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.05; **: p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.01; ***: p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.001). Users can identify genes that are up-regulated or down-regulated in the tumors compared to normal tissues for each cancer type, as displayed in gray columns when normal data are available\u003csup\u003e\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e \u003ch2\u003eCompeting interests\u003c/h2\u003e \u003cp\u003eThe authors declare no competing interests.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003e \u003cb\u003eEthics declarations\u003c/b\u003e \u003c/h2\u003e \u003cp\u003e \u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e \u003cp\u003e This project was approved by the Institutional Review Boards of the University of Alabama at Birmingham(IRB-300011620). Due to the retrospective nature of the study, Institutional Review Board waived the need of obtaining informed consent.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eConception and design: BN, CL, HG, JX; providing access to clinical samples: BN, HG; Performing experiments, ethics approval, pathological reviews, acquisition of data, analysis and interpretation of data: BN, CL, ACK, JZ, HJ, ZZ, YZ, YD, YC, HG, JX; Statistical support: BN, YC; Drafted the manuscript: BN, CL, JX. All authors read and approved the final manuscript; overall study supervision: GH, JX.\u003c/p\u003e\u003ch2\u003eAcknowledgments:\u003c/h2\u003e \u003cp\u003eThis research was supported in part by the Startup Fund and Impact Award from the Heersink School of Medicine at the University of Alabama at Birmingham (to J. Xu) and the Breast Cancer Research Foundation of Alabama (to J. Xu). RPPA dataset has been performed by a core facility at the University of Texas-M.D. Anderson Cancer Center at Houston.\u003c/p\u003e\u003ch2\u003eData Availability\u003c/h2\u003e\u003cp\u003e Data is provided within the manuscript or supplementary information files.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eCiriello, G. et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. \u003cem\u003eCell\u003c/em\u003e. \u003cb\u003e163\u003c/b\u003e, 506\u0026ndash;519. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.cell.2015.09.033\u003c/span\u003e\u003cspan address=\"10.1016/j.cell.2015.09.033\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eParker, J. S. et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. \u003cem\u003eJ. Clin. Oncol.\u003c/em\u003e \u003cb\u003e41\u003c/b\u003e, 4192\u0026ndash;4199. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1200/JCO.22.02511\u003c/span\u003e\u003cspan address=\"10.1200/JCO.22.02511\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiedtke, C. et al. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. \u003cem\u003eJ. Clin. Oncol.\u003c/em\u003e \u003cb\u003e41\u003c/b\u003e, 1809\u0026ndash;1815. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1200/JCO.22.02572\u003c/span\u003e\u003cspan address=\"10.1200/JCO.22.02572\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKohler, B. A. et al. Annual Report to the Nation on the Status of Cancer, 1975\u0026ndash;2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. \u003cem\u003eJ Natl Cancer Inst\u003c/em\u003e 107, djv048 (2015). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/jnci/djv048\u003c/span\u003e\u003cspan address=\"10.1093/jnci/djv048\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. \u003cem\u003eClin. Cancer Res.\u003c/em\u003e \u003cb\u003e13\u003c/b\u003e, 4429\u0026ndash;4434 (2007).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCarey, L. A. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. \u003cem\u003eClin. Cancer Res.\u003c/em\u003e \u003cb\u003e13\u003c/b\u003e, 2329\u0026ndash;2334 (2007).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. \u003cem\u003eJ. Clin. Invest.\u003c/em\u003e \u003cb\u003e121\u003c/b\u003e, 2750\u0026ndash;2767. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1172/JCI45014\u003c/span\u003e\u003cspan address=\"10.1172/JCI45014\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2011).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFerreira, A. R., Metzger-Filho, O., Sarmento, R. M. B. \u0026amp; Bines, J. Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02). \u003cem\u003eFront. Oncol.\u003c/em\u003e \u003cb\u003e7\u003c/b\u003e, 329. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3389/fonc.2017.00329\u003c/span\u003e\u003cspan address=\"10.3389/fonc.2017.00329\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEmens, L. A. et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. \u003cem\u003eAnn. Oncol.\u003c/em\u003e \u003cb\u003e32\u003c/b\u003e, 983\u0026ndash;993. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.annonc.2021.05.355\u003c/span\u003e\u003cspan address=\"10.1016/j.annonc.2021.05.355\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCoates, A. S. et al. Tailoring therapies\u0026ndash;improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. \u003cem\u003eAnn. Oncol.\u003c/em\u003e \u003cb\u003e26\u003c/b\u003e, 1533\u0026ndash;1546. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/annonc/mdv221\u003c/span\u003e\u003cspan address=\"10.1093/annonc/mdv221\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCarey, L. A. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. \u003cem\u003eClin. Cancer Res.\u003c/em\u003e \u003cb\u003e13\u003c/b\u003e, 2329\u0026ndash;2334. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1158/1078-0432.CCR-06-1109\u003c/span\u003e\u003cspan address=\"10.1158/1078-0432.CCR-06-1109\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2007).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSharma, P. et al. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. \u003cem\u003eClin. Cancer Res.\u003c/em\u003e \u003cb\u003e23\u003c/b\u003e, 649\u0026ndash;657. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1158/1078-0432.CCR-16-0162\u003c/span\u003e\u003cspan address=\"10.1158/1078-0432.CCR-16-0162\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYau, C. et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. \u003cem\u003eLancet Oncol.\u003c/em\u003e \u003cb\u003e23\u003c/b\u003e, 149\u0026ndash;160. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/S1470-2045(21)00589-1\u003c/span\u003e\u003cspan address=\"10.1016/S1470-2045(21)00589-1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShepherd, J. H. et al. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. \u003cem\u003eJ. Clin. Oncol.\u003c/em\u003e \u003cb\u003e40\u003c/b\u003e, 1323\u0026ndash;1334. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1200/JCO.21.01506\u003c/span\u003e\u003cspan address=\"10.1200/JCO.21.01506\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003evon Minckwitz, G. et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. \u003cem\u003eLancet Oncol.\u003c/em\u003e \u003cb\u003e15\u003c/b\u003e, 747\u0026ndash;756. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/S1470-2045(14)70160-3\u003c/span\u003e\u003cspan address=\"10.1016/S1470-2045(14)70160-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2014).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGeyer, C. E. et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. \u003cem\u003eAnn. Oncol.\u003c/em\u003e \u003cb\u003e33\u003c/b\u003e, 384\u0026ndash;394. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.annonc.2022.01.009\u003c/span\u003e\u003cspan address=\"10.1016/j.annonc.2022.01.009\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNewman, L. A. \u0026amp; Kaljee, L. M. Health Disparities and Triple-Negative Breast Cancer in African American Women: A Review. \u003cem\u003eJAMA Surg.\u003c/em\u003e \u003cb\u003e152\u003c/b\u003e, 485\u0026ndash;493. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1001/jamasurg.2017.0005\u003c/span\u003e\u003cspan address=\"10.1001/jamasurg.2017.0005\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKohler, B. A. et al. Annual Report to the Nation on the Status of Cancer, 1975\u0026ndash;2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. \u003cem\u003eJ Natl Cancer Inst\u003c/em\u003e 107, djv048 (2015). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/jnci/djv048\u003c/span\u003e\u003cspan address=\"10.1093/jnci/djv048\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePrakash, O. et al. Racial Disparities in Triple Negative Breast Cancer: A Review of the Role of Biologic and Non-biologic Factors. \u003cem\u003eFront. Public. Health\u003c/em\u003e. \u003cb\u003e8\u003c/b\u003e, 576964. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3389/fpubh.2020.576964\u003c/span\u003e\u003cspan address=\"10.3389/fpubh.2020.576964\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKillelea, B. K. et al. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. \u003cem\u003eJ. Clin. Oncol.\u003c/em\u003e \u003cb\u003e33\u003c/b\u003e, 4267\u0026ndash;4276. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1200/JCO.2015.63.7801\u003c/span\u003e\u003cspan address=\"10.1200/JCO.2015.63.7801\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBandera, E. V., Maskarinec, G., Romieu, I. \u0026amp; John, E. M. Racial and ethnic disparities in the impact of obesity on breast cancer risk and survival: a global perspective. \u003cem\u003eAdv. Nutr.\u003c/em\u003e \u003cb\u003e6\u003c/b\u003e, 803\u0026ndash;819. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3945/an.115.009647\u003c/span\u003e\u003cspan address=\"10.3945/an.115.009647\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCarmena, M. \u0026amp; Earnshaw, W. C. The cellular geography of aurora kinases. \u003cem\u003eNat. Rev. Mol. Cell. Biol.\u003c/em\u003e \u003cb\u003e4\u003c/b\u003e, 842\u0026ndash;854. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/nrm1245\u003c/span\u003e\u003cspan address=\"10.1038/nrm1245\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2003).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLens, S. M., Voest, E. E. \u0026amp; Medema, R. H. Shared and separate functions of polo-like kinases and aurora kinases in cancer. \u003cem\u003eNat. Rev. Cancer\u003c/em\u003e. \u003cb\u003e10\u003c/b\u003e, 825\u0026ndash;841. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/nrc2964\u003c/span\u003e\u003cspan address=\"10.1038/nrc2964\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2010).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKeen, N. \u0026amp; Taylor, S. Aurora-kinase inhibitors as anticancer agents. \u003cem\u003eNat. Rev. Cancer\u003c/em\u003e. \u003cb\u003e4\u003c/b\u003e, 927\u0026ndash;936. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/nrc1502\u003c/span\u003e\u003cspan address=\"10.1038/nrc1502\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2004).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGarlapati, C. et al. PLK1 and AURKB phosphorylate survivin differentially to affect proliferation in racially distinct triple-negative breast cancer. \u003cem\u003eCell. Death Dis.\u003c/em\u003e \u003cb\u003e14\u003c/b\u003e, 12. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41419-022-05539-5\u003c/span\u003e\u003cspan address=\"10.1038/s41419-022-05539-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBush, T. L. et al. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models. \u003cem\u003eMol. Cancer Ther.\u003c/em\u003e \u003cb\u003e12\u003c/b\u003e, 2356\u0026ndash;2366. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1158/1535-7163.MCT-12-1178\u003c/span\u003e\u003cspan address=\"10.1158/1535-7163.MCT-12-1178\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2013).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePalma, G. et al. Triple negative breast cancer: looking for the missing link between biology and treatments. \u003cem\u003eOncotarget\u003c/em\u003e. \u003cb\u003e6\u003c/b\u003e, 26560\u0026ndash;26574. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.18632/oncotarget.5306\u003c/span\u003e\u003cspan address=\"10.18632/oncotarget.5306\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003evan Diest, P. J., Brugal, G. \u0026amp; Baak, J. P. Proliferation markers in tumours: interpretation and clinical value. \u003cem\u003eJ. Clin. Pathol.\u003c/em\u003e \u003cb\u003e51\u003c/b\u003e, 716\u0026ndash;724. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1136/jcp.51.10.716\u003c/span\u003e\u003cspan address=\"10.1136/jcp.51.10.716\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (1998).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRakha, E. A. et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. \u003cem\u003eJ. Clin. Oncol.\u003c/em\u003e \u003cb\u003e26\u003c/b\u003e, 3153\u0026ndash;3158. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1200/JCO.2007.15.5986\u003c/span\u003e\u003cspan address=\"10.1200/JCO.2007.15.5986\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2008).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eArispe Angulo, K. R. et al. A high mitotic score in breast cancer after neoadjuvant chemotherapy is predictive of outcome and associated with a distinct morphology. \u003cem\u003eHistopathology\u003c/em\u003e. \u003cb\u003e76\u003c/b\u003e, 661\u0026ndash;670. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/his.14049\u003c/span\u003e\u003cspan address=\"10.1111/his.14049\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBurstein, M. D. et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. \u003cem\u003eClin. Cancer Res.\u003c/em\u003e \u003cb\u003e21\u003c/b\u003e, 1688\u0026ndash;1698. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1158/1078-0432.CCR-14-0432\u003c/span\u003e\u003cspan address=\"10.1158/1078-0432.CCR-14-0432\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKim, S. et al. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers. \u003cem\u003eClin. Breast Cancer\u003c/em\u003e. \u003cb\u003e18\u003c/b\u003e, e1123\u0026ndash;e1132. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.clbc.2018.03.012\u003c/span\u003e\u003cspan address=\"10.1016/j.clbc.2018.03.012\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhao, S. et al. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. \u003cem\u003eOncologist\u003c/em\u003e. \u003cb\u003e25\u003c/b\u003e, e1481\u0026ndash;e1491. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1634/theoncologist.2019-0982\u003c/span\u003e\u003cspan address=\"10.1634/theoncologist.2019-0982\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. \u003cem\u003eNature\u003c/em\u003e. \u003cb\u003e527\u003c/b\u003e, 472\u0026ndash;476. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/nature15748\u003c/span\u003e\u003cspan address=\"10.1038/nature15748\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHirota, T., Lipp, J. J., Toh, B. H. \u0026amp; Peters, J. M. Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. \u003cem\u003eNature\u003c/em\u003e. \u003cb\u003e438\u003c/b\u003e, 1176\u0026ndash;1180 (2005).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHsu, J. Y. et al. Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. \u003cem\u003eCell\u003c/em\u003e. \u003cb\u003e102\u003c/b\u003e, 279\u0026ndash;291 (2000).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKettenbach, A. N. et al. Quantitative phosphoproteomics identifies substrates and functional modules of Aurora and Polo-like kinase activities in mitotic cells. \u003cem\u003eSci. Signal.\u003c/em\u003e \u003cb\u003e4\u003c/b\u003e, rs5. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1126/scisignal.2001497\u003c/span\u003e\u003cspan address=\"10.1126/scisignal.2001497\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2011).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTyler, R. K., Shpiro, N., Marquez, R. \u0026amp; Eyers, P. A. VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. \u003cem\u003eCell. Cycle\u003c/em\u003e. \u003cb\u003e6\u003c/b\u003e, 2846\u0026ndash;2854 (2007).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWoriax, H. E. et al. Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy. \u003cem\u003eJ. Clin. Oncol.\u003c/em\u003e \u003cb\u003eJCO2301199\u003c/b\u003e \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1200/JCO.23.01199\u003c/span\u003e\u003cspan address=\"10.1200/JCO.23.01199\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2024).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSullivan, H. C. et al. Triple-negative breast carcinoma in African American and Caucasian women: clinicopathology, immunomarkers, and outcome. \u003cem\u003eAppl. Immunohistochem. Mol. Morphol.\u003c/em\u003e \u003cb\u003e22\u003c/b\u003e, 17\u0026ndash;23. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1097/PAI.0b013e318281148e\u003c/span\u003e\u003cspan address=\"10.1097/PAI.0b013e318281148e\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2014).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMremi, A. et al. Breast cancer in Tanzanian, black American, and white American women: An assessment of prognostic and predictive features, including tumor infiltrating lymphocytes. \u003cem\u003ePLoS One\u003c/em\u003e. \u003cb\u003e14\u003c/b\u003e, e0224760. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1371/journal.pone.0224760\u003c/span\u003e\u003cspan address=\"10.1371/journal.pone.0224760\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStuart-Harris, R., Caldas, C., Pinder, S. E. \u0026amp; Pharoah, P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. \u003cem\u003eBreast\u003c/em\u003e. \u003cb\u003e17\u003c/b\u003e, 323\u0026ndash;334. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.breast.2008.02.002\u003c/span\u003e\u003cspan address=\"10.1016/j.breast.2008.02.002\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2008).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. \u003cem\u003eJ. Clin. Invest.\u003c/em\u003e \u003cb\u003e121\u003c/b\u003e, 2750\u0026ndash;2767. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1172/JCI45014\u003c/span\u003e\u003cspan address=\"10.1172/JCI45014\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2011).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKivinummi, K. et al. The expression of AURKA is androgen regulated in castration-resistant prostate cancer. \u003cem\u003eSci. Rep.\u003c/em\u003e \u003cb\u003e7\u003c/b\u003e, 17978. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41598-017-18210-3\u003c/span\u003e\u003cspan address=\"10.1038/s41598-017-18210-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBalko, J. M. et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. \u003cem\u003eCancer Discov\u003c/em\u003e. \u003cb\u003e4\u003c/b\u003e, 232\u0026ndash;245. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1158/2159-8290.CD-13-0286\u003c/span\u003e\u003cspan address=\"10.1158/2159-8290.CD-13-0286\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2014).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAnand, U. et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. \u003cem\u003eGenes Dis.\u003c/em\u003e \u003cb\u003e10\u003c/b\u003e, 1367\u0026ndash;1401. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.gendis.2022.02.007\u003c/span\u003e\u003cspan address=\"10.1016/j.gendis.2022.02.007\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMatsuyama, A. et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. \u003cem\u003eEMBO J.\u003c/em\u003e \u003cb\u003e21\u003c/b\u003e, 6820\u0026ndash;6831. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/emboj/cdf682\u003c/span\u003e\u003cspan address=\"10.1093/emboj/cdf682\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2002).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKai, K. et al. Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. \u003cem\u003eMol. Cancer Ther.\u003c/em\u003e \u003cb\u003e14\u003c/b\u003e, 2687\u0026ndash;2699. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1158/1535-7163.MCT-15-0096\u003c/span\u003e\u003cspan address=\"10.1158/1535-7163.MCT-15-0096\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKawai, M., Nakashima, A., Kamada, S. \u0026amp; Kikkawa, U. Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family. \u003cem\u003eJ. Biomed. Sci.\u003c/em\u003e \u003cb\u003e22\u003c/b\u003e, 48. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/s12929-015-0150-2\u003c/span\u003e\u003cspan address=\"10.1186/s12929-015-0150-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYang, G. et al. Career choice regret during COVID-19 among healthcare students and professionals in mainland China: a cross-sectional study. \u003cem\u003eBMC Med. Educ.\u003c/em\u003e \u003cb\u003e21\u003c/b\u003e, 534. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/s12909-021-02972-6\u003c/span\u003e\u003cspan address=\"10.1186/s12909-021-02972-6\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXu, J. et al. AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway-Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B. \u003cem\u003eCancer Discov\u003c/em\u003e. \u003cb\u003e11\u003c/b\u003e, 3064\u0026ndash;3089. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1158/2159-8290.CD-20-0815\u003c/span\u003e\u003cspan address=\"10.1158/2159-8290.CD-20-0815\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXu, J. et al. 14-3-3zeta turns TGF-beta's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. \u003cem\u003eCancer Cell.\u003c/em\u003e \u003cb\u003e27\u003c/b\u003e, 177\u0026ndash;192. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.ccell.2014.11.025\u003c/span\u003e\u003cspan address=\"10.1016/j.ccell.2014.11.025\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. \u003cem\u003eNucleic Acids Res.\u003c/em\u003e \u003cb\u003e48\u003c/b\u003e, W509\u0026ndash;W514. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/nar/gkaa407\u003c/span\u003e\u003cspan address=\"10.1093/nar/gkaa407\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"TNBC, Cancer Disparity, AURKA, AURKB, Neoadjuvant Chemotherapy","lastPublishedDoi":"10.21203/rs.3.rs-4889272/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4889272/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eNowadays, chemotherapy and immunotherapy remain the major treatment strategies for Triple-Negative Breast Cancer (TNBC). Identifying biomarkers to pre-select and subclassify TNBC patients with distinct chemotherapy responses is essential. In the current study, we performed an unbiased Reverse Phase Protein Array (RPPA) on TNBC cells treated with chemotherapy compounds and found a leading significant increase of phosphor-AURKA/B/C, AURKA, AURKB, and PLK1, which fall into the mitotic kinase group. The increase of AURKA and AURKB protein was majorly due to a post-transcription level regulation, and Paclitaxel treatment induced Aurora Kinases protein phosphorylation on AURKA(T288)/AURKB(T232) sites and their protein stability. In our UAB TNBC cohort, the expression of AURKA and AURKB was significantly higher in TNBC tumors compared to normal adjacent tissues, and AURKB was found to be highly expressed in African American TNBC patients compared to European Americans. Moreover, Aurora Kinases overexpression in TNBC cells renders resistance to Paclitaxel treatment and attenuates the apoptosis effect triggered by chemotherapy treatment, suggesting Aurora Kinases could mediate the chemo-resistance in TNBC. Hence, a combination of Aurora kinase inhibitors or PROTAC degrader and taxane-type chemotherapy significantly enhanced the chemotherapy effect. In summary, we revealed that Aurora Kinases upregulation after treatment with chemotherapy could confer chemotherapy resistance to TNBC cells, and AURKB could serve as preselection markers for stratifying patients\u0026rsquo; response to neoadjuvant chemotherapy.\u003c/p\u003e","manuscriptTitle":"Proteomic Profiling Identifies Upregulation of Aurora Kinases Causing Resistance to Taxane-type Chemotherapy in Triple Negative Breast Cancer","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-10-15 08:24:45","doi":"10.21203/rs.3.rs-4889272/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-12-02T04:47:22+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-12-02T01:39:33+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-11-30T19:50:08+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-11-28T07:06:03+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"112356593581636671404193154593956558187","date":"2024-11-19T04:45:52+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"240385953867526049127629182364477534912","date":"2024-11-19T03:44:43+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"278320808301444764554308484628584902085","date":"2024-11-19T03:11:50+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"327681405341667279791497853996121682352","date":"2024-11-18T21:41:43+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"240881504032035237032538493323559609293","date":"2024-11-18T16:34:07+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-11-18T16:29:45+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-08-22T15:55:40+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2024-08-22T06:22:56+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-08-21T05:43:14+00:00","index":"","fulltext":""},{"type":"submitted","content":"Scientific Reports","date":"2024-08-09T22:34:50+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"ae716a0e-b995-4d42-8992-1d848b319287","owner":[],"postedDate":"October 15th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":37738593,"name":"Biological sciences/Cancer"},{"id":37738594,"name":"Biological sciences/Cancer/Breast cancer"},{"id":37738595,"name":"Health sciences/Oncology/Cancer"},{"id":37738596,"name":"Health sciences/Oncology/Cancer/Cancer therapy/Chemotherapy"}],"tags":[],"updatedAt":"2025-01-27T15:59:48+00:00","versionOfRecord":{"articleIdentity":"rs-4889272","link":"https://doi.org/10.1038/s41598-025-87315-x","journal":{"identity":"scientific-reports","isVorOnly":false,"title":"Scientific Reports"},"publishedOn":"2025-01-25 15:57:07","publishedOnDateReadable":"January 25th, 2025"},"versionCreatedAt":"2024-10-15 08:24:45","video":"","vorDoi":"10.1038/s41598-025-87315-x","vorDoiUrl":"https://doi.org/10.1038/s41598-025-87315-x","workflowStages":[]},"version":"v1","identity":"rs-4889272","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4889272","identity":"rs-4889272","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}